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ABSTRACT 
Fluorescent bioimaging has proven to be a powerful tool in non-invasively studying 
biological processes in living systems. One application of this technique is being used in a 
transgenic zebrafish model to study the innate immune response to infection of Candida 
Albicans. Methods utilizing genetic engineering, however, are limited by time constraints 
that arise when having to depend upon the ability to modify genetics of the model. To 
bypass these constraints, this project seeks to produce a modified version of a previously 
developed biofluorescent probe, which was validated in a mouse model. The probe consists 
of three components, a hexapeptide, a fluorophore, and a polyethylene glycol (PEG) 
polymer. The peptide was found to bind to the formyl peptide receptors (FPRs) of the 
neutrophils in mice. Synthesis of this peptide was accomplished using solid phase peptide 
synthesis and standard Fmoc-chemistry. The peptide was purified via high performance 
liquid chromatography (HPLC), and characterized via mass spectrometry and 1H NMR and 
13C NMR. The product had a yield of 9 mg. The PEG polymer serves to increase 
bioavailability and was conjugated to the peptide in sodium borate acetonitrile buffer 
system. This molecule was characterized via MALDI mass spectrometry and resulted in a 
yield of 4.9 mg. Further studies will verify the successful conjugation of the fluorophore 
to the PEG polymer. Once characterized, the probe will be validated through application 
to an unmodified zebrafish model. 
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CHAPTER 1: INTRODUCTION 
 The role of the innate immune system in the presence of infection has been of great 
interest to researchers in recent years. Bioimaging is a technique that involves molecular-
guided imaging of living systems at the cellular level.1 It is unique in that it enables the 
analysis of cellular interactions at the molecular level and is being developed to be utilized 
in research and clinical settings for diagnostics and treatment of disease.2 Bioimaging is 
powerful due to the nature in how it enables researchers to essentially “see” and visually 
observe cellular events and interactions. Furthermore, this technique may be performed on 
biological systems in vitr o as well as in vivo, allowing for visualization in real-time. It also 
provides information concerning the localization and quantity of the molecules of interest. 
As a result, bioimaging has further expanded possibilities in biological research by the level 
of information it can provide researchers.  
The hallmark feature of bioimaging is the probe that is used for visualization. The 
probe is a molecule that is designed specifically for the cellular interaction of interest and 
is modified to include a molecular component that will enable visualization, usually a 
fluorescent dye or a radiolabel.1 Reflective of the vast diversity of cellular interactions that 
occur in a living system as complex as the human body, a number of different probes have 
been developed to investigate these interactions, showing the versatility of this technique. 
One application of the bioimaging technique has been to investigate the role of the 
innate immune system in the presence of infection.3 Currently, there are studies to 
understand the mechanisms of the innate immune response in a host infected with the 
microbe Candida Albicans (C. albicans).4 Currently, researchers are using a method of 
fluorescent imaging that involves use of a fluorescent transgenic zebrafish model to 
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visualize the cellular interactions of the zebrafish neutrophil. However, a bioactive probe 
is of interest to provide an alternative synthetic approach to bioimaging these models, and 
further understanding the role of the innate immune system in the presence of infection in 
human systems.  
1.1. General characteristics of the innate immune system and response in humans 
Humans contain and carry a plethora of different microbes that reside on all surfaces of the 
body. The body contains at least 10 times more bacterial cells than it does human cells.5 
Many of these microbes thrive in colonies throughout the body and maintain a commensal 
relationship with the host, and some others even share a mutualistic-type of relationship. 
Infection occurs when a microbe enters the host organism and multiplies to a point of 
overgrowth, and the number of organisms is no longer in a state of equilibrium with the 
host.6 Disease differs from infection in that it affects a small percentage of infected people 
and causes damage to cells of the body.5 
In general, the immune system is comprised of many different cells that work alone 
and together in different combinations against different types of attacks on the body. 
Historically, the immune system was regarded as two systems, the innate response and the 
adaptive response.7 Another subcategory is comprised of anatomical and physiological 
barriers against foreign substances, pathogens, and any other cells that are not compatible 
with the host organism. After the anatomical and physiological barriers were breached, it 
was concluded that the innate immune response was the host organism’s first line of 
defense against infection. The innate system was considered to be a non-specific, but 
immediate response, and was overlooked by the next line of defense, the adaptive immune 
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response, which was considered to be a specific mode of defense and much more 
sophisticated. However, in recent years, research has proven the importance of the innate 
immune system through a greater understanding of its role in infection and disease.  
When infection occurs, the innate immune response is activated by the recognition 
of the microbes and danger signals that are released from host cells that have been 
damaged.8 A hallmark of the innate immune system is its mediation via phagocytic cells, 
such as macrophages and neutrophils. Understanding the differences, roles, and 
mechanisms of these different cells are important to fully understanding the process of 
innate immunity. Conveniently, the nature of these cells can be investigated through the 
use of fluorescence bioimaging. 
Neutrophils are of specific interest in studying host defense and innate immunity 
response. These cells are major pathogen-fighting agents in the body.9 The ability to be 
quickly recruited to sites of infection and inflammation, to recognize and phagocytose 
microbes, and kill pathogens through phagocytic and cytotoxic mechanisms are hallmarks 
of the neutrophils, and are characteristics that make the cell so remarkable. Additionally, 
recent research has suggested that there is a line of communication between neutrophils, 
macrophages, and adaptive immune system. Originally, it was thought that neutrophils 
were only present during the acute stage of infection, but evidence shows that neutrophils 
play a larger role in influencing the immune system.  
1.2. General characteristics of bioactive peptides and their role in bioimaging 
Bioactive peptides have been broadly defined as protein fragments that have a 
positive or negative effect on body functions or conditions and may have an influence on 
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health.11 These molecules have been found to exist in all living systems, and play critical 
roles in a variety of functions such as the immune response in the presence of infection and 
the regulation of blood pressure and glucose levels.10 They are derived from a variety of 
sources, such as food and bacteria, and a number of biological mechanisms have been 
proposed in regards to these peptides’ roles in the human body systems (Figure 1.1).  
 
 
 
Figure 1. 1 Several proposed biological mechanisms for different bioactive peptides, including anti-diabetes 
effects, anti-obesity effects, and anti-inflammation effects [Adapted from Li, et al., 2017].10  
 
These molecules are of interest for therapeutic targets, based on their binding 
characteristics to specific protein receptors. Drug molecules are being developed which 
utilize bioactive moieties to selectively deliver encapsulated drugs, by targeting the protein 
receptors that may be found on the surface of the cell of interest.12 This same principle is 
being adapted for molecular-guided imaging technique. 
 
 
 
5 
 
 
Figure 1. 2 A cartoon depiction magnifying the surface of a neutrophil and showing the transmembrane 
formyl peptide receptors [Adapted from Tsai, et al., 2016].13  
 
For this project, the specific binding function of bioactive peptides will be utilized 
for targeting the neutrophil cells of the zebrafish model for imaging, but will be modified 
to have molecules useful for fluorescent imaging techniques. On the surface of the 
neutrophil cells are protein receptors called formyl peptide receptors (FPRs) (Figure 1.2).14 
There are three known types of these receptors, FPR1, FPR2, and FPR3. These receptors 
are part of a larger class of receptors called G-protein coupled receptors (GPCRs), which 
are involved in the recruitment of neutrophils in inflammatory events. However, they can 
also be repurposed as receptors to bind a bioactive peptide modified with a fluorescent tag 
to image neutrophil interactions with high selectivity. Studies have shown that these three 
receptors do not always bind the same ligands.15 This aspect could be useful in developing 
a peptide designed to target a specific FPR. 
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1.3. The transgenic model and its application to study a host-pathogen interaction 
 
Candida Albicans (C. albicans) is the most abundant type of fungal species in the 
human microbiota.6 These organisms typically colonize different areas of the body, 
commonly the gastrointestinal and genitourinary tracts. In healthy individuals, the species 
falls into the commensal-type relationship with its host. However, in some cases when 
alteration has occurred to the host microbiota or when alteration has occurred in the host 
immunity, overgrowth of C. albicans can occur. It is the overgrowth of the fungi that results 
in a wide range of infections within the host, such as commonly known yeast infections 
and diaper rash. C. albicans is of the few fungal species that is disease-causing in humans. 
It is a microorganism of great interest due to its notoriety for forming biofilms on various 
medical devices, which presents a challenge in clinical settings to prevent patient infection. 
This organism alone accounts for 15% of nosocomial sepsis cases.16 
The impact C. albicans has on human health has created a push to further 
understanding the role of the innate immune system response in the event of infection. 
Having knowledge of this response mechanism could provide insight for therapeutics and 
drug development. The zebrafish model is one tool researchers have used to study the 
mechanisms of a wide range of infections in a preclinical setting, including that of C. 
albicans.8,4  
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Figure 1. 3 A timeline showing the three hallmark stages of zebrafish development [Adapted from Masud, 
et al., 2017]8 
 
The zebrafish is an efficient model for a number of reasons. Similar to humans, the 
immune response in zebrafish is a cooperative function between the innate and adaptive 
immune systems. Further, the adaptive immune response in zebrafish matures much later 
than the innate, thus zebrafish larvae are a prime candidate for studying innate immunity 
in separation from the adaptive immune system (Figure 1.3). There is a window in which 
the organism has not developed an adaptive immune response. Development of the 
adaptive immune system is indicative by the presence of T cells. 
 Another major benefit of using zebrafish is the optimized optical accessibility the 
specimen provides as a result of its transparent tissues. Finally, zebrafish embryos are 
readily and easily colonized by commensal flora that are commonly found on surfaces of 
the human body. Over the past decade, embryonic, larval, and adult zebrafish have been 
used in a range of models to study the complexities of immune response.8  
Another important aspect of the zebrafish model is the availability of genetically 
engineered specimen which have been altered to express fluorescently actively proteins. 
 
 
8 
The genome of the model of interest in this research project has been transformed to include 
either the mpx:GFP or mpx:mCherry transgene. 4 In essence, the myeloperoxidase 
promoter is included in the organism’s genome, which promotes the neutrophil-specific 
expression of either the proteins green fluorescent protein (GFP) or the mCherry protein. 
These proteins absorb and emit light at different wavelengths, but both within the visible 
range, allowing for fluorescent imaging studies to be performed to visualize the cellular 
interactions of the neutrophils. Furthermore, the wavelengths at which these proteins 
fluoresce differ enough from the wavelengths that cause macrophages to fluoresce, which 
ensures the ability to selectively visualize neutrophil cells.  
While a useful method for imaging cellular interactions of neutrophils, this method 
is tedious in its reliance on genetics. In the event that a fishline lacks the promoter necessary 
to expresses fluorescently active proteins, the issue may be remedied by crossing fishlines. 
However, the amount of time necessary to produce a functional model is costly to the flow 
of research and is a disadvantage to this means of imaging. A synthetic alternative that can 
be introduced to the zebrafish model endogenously is of interest in order to remove the 
time hindrance associated with current methods while maintaining imaging functionality. 
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1.4 Current bioactive probes designed to target study of the innate immune system 
 
As previously discussed, a number of bioactive probes have been developed for use 
in bioimaging techniques. One such probe was developed by a research group at the 
University of Virginia that targets the FPRs on the surface of neutrophil cells in mice.17 
This probe consisted of three components, a bioactive peptide, a polyethylene glycol (PEG) 
polymer, and a Cyanine 7 fluorophore (Figure 1.4). 
 
 
(a) 
 
 
(b) 
 
Figure 1. 4 (a) Hybrid structure of the bioactive probe developed by Xiao, et al [Adapted from Xiao, et al., 
2010].17 The complex includes a short hexapeptide capped with a cinnamoyl, cFLFLFK, a polyethylene 
glycol (PEG) polymer and a Cyanine 7 fluorophore. (b) A graphical depiction of a bioactive probe developed 
to selectively target the FPRs on the neutrophils in mice [Adapted from Riedel, 2013].18  
 
Because the functionality of the bioactive probe depends solely on the bioactive 
peptide that serves as the foundation, design of the bioactive peptide is important when 
developing imaging probes. Figure 1.5 compares a few known ligands that have binding 
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affinities FPRs (a) to the structure of the peptide designed for use as a bioactive probe 
specific to mouse neutrophils.  
 
(a) 
 
 
 
(b) 
 
Figure 1. 5 (a) Some known N-formylated ligands with binding affinities for FPRs [Adapted from Ye, et al., 
2017].15 (b) Structure of the target bioactive peptide, cFLFLFK.  
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One similarity between some of the known ligands and the target molecule is the 
presence of phenylalanine residues and leucine residues (Figure 1.5a in purple and yellow, 
respectively). Another element in peptide ligands for FPRs are the presence of N-
formylated methionine residues.19 The mechanism of this binding event is not clear, but 
studies have shown that N-formylated peptides with a methionine residue at the the N-
terminus commonly act as ligands to FPRs. The peptide highlighted in purple has a 
methionine residue at the N-terminus and has been formylated (Figure 1.5a). The target 
peptide (Figure 1.5b) is not formylated, nor does it include a methionine residue. However, 
the cinnamoyl cap on the target peptide may mimic the effects of the N-formylated 
methionine residue, in that it promotes binding to the FPR. It may also increase antagonistic 
characteristics of the peptide, so that it binds to the FPR but does not result in signal 
transduction. In essence, the peptide would have similar binding affinities, but the 
neutrophil would not recognize the peptide as a recruiting molecule to elicit an immune 
response against the peptide. 
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Figure 1. 6 Overview of solid phase peptide synthesis using standard Fmoc-chemistry to produce the peptide 
cFLFLFK.  
 
For synthesis of the bioactive probe, first the peptide was produced via automated 
solid phase peptide synthesis using standard Fmoc-chemistry.20 In solid phase synthesis, 
there are two main steps that make up one coupling cycle of an amino acid fragment (Figure 
1.6). The first step involves the removal of a protecting group, fluorenylmethyloxycarbonyl 
(Fmoc), from the terminal amine of the peptide chain. In the Figure above the Nα that is 
deprotected is the amine on the terminal end of the solid support (denoted as PS). In 
subsequent coupling cycles, the amine to undergo deprotection will be a part of the peptide 
backbone. This functional group is used to control the reactivity of the terminal amine 
throughout reactions and reduces the likelihood of a doubling coupling event to occur 
throughout the synthesis.21 Another protecting group, tert-butyloxycarbonyl (Boc), is used 
to control the reactivity of the terminal amine of the lysine residue side chain, so to prevent 
side chain reactions from occurring.22 
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 The use of protecting groups for Nα-amino protection is an important feature in 
solid phase peptide synthesis techniques.21 The Fmoc group replaced the previously 
preferred Boc group due to the milder conditions necessary for removal of the Fmoc group. 
Deprotection of Fmoc requires a mild base, such as 4-methylpiperidine, whereas the Boc 
group becomes labile in acidic conditions. The milder conditions allowed for the 
elimination of repetitive acidolysis steps and the final strong acidolysis step which were 
hallmarks of solid phase synthesis that used Boc group for Nα protection. This 
characteristic is also more compatible with peptides that are susceptible to acid-catalyzed 
side reactions, making the Fmoc compound a more efficient protecting group. However, 
the compatibility between these two molecules based on their stabilities in different 
conditions (basic/acidic) allows for selective deprotection of Nα-amino groups and 
selective protection of reactive side chains throughout the synthesis of the peptide. 
After deprotection, the first amino acid residue may be loaded onto the resin in the 
next step. A coupling agent is used, 2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU), to activate the carboxylic acid of the 
incoming amino acid fragment. Then the carboxylic acid donates the acyl group, which 
forms the peptide bond. The peptide bond presents a nucleophilic attack on the α-amino 
group of another amino acid.22 The incoming amino acid residue is also protected with an 
Fmoc group, so to load the next amino acid the cycle begins again with removal of the 
Fmoc group. Upon completion, the peptide can be released from the solid support under 
strong acidic conditions. This step also globally deprotects the Boc-protected sidechains. 
Stepwise, peptides can be synthesized from the C to the N terminus using N𝛼-protected 
amino acids.23 
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The modification to the peptide to include a PEG polymer was found to be 
necessary to increase the bioavailability of the peptide.17 The peptide is composed of 
largely non-polar amino acid residues (phenylalanine and leucine), further it is capped with 
the cinnamoyl group at the N-terminus and the C-terminus has been functionalized with an 
amide, rather than the typical carboxylate group. As a result, the peptide is highly 
hydrophobic and its ability to remain in biological systems proved itself a challenge. A 
PEG polymer of 3.4 KDa (76 repeat units) was determined to be a sufficient length to 
increase the bioavailability and ensure the peptide could exist in aqueous environments 
(i.e. when injected into the bloodstream if a mouse model). This molecule was attached to 
the terminal amine of the lysine residue side chain through a conjugative addition reaction 
in a 0.1 M acetonitrile sodium borate buffer system (pH 8.5). 
 The selection of the Cyanine 7 (Cy7) fluorophore was based on its emission 
wavelength, 800 nm, which is in the near-infrared region (NIR). This was necessary due to 
the application of the probe to a mouse model. At the NIR region, mammalian tissue has 
low absorbance, thus the signal could better penetrate through the tissue. Fluorophores 
chosen in the visible range would be difficult to visualize. This compound was conjugated 
to the terminal amine of the PEG76 molecule using similar conditions to attach the PEG 
polymer to the peptide.  
 The completed probe was synthesized using the methods previously described. In 
addition to the target molecule, a series of derivatives were produced as well, with slight 
modifications made. These modifications included varying lengths of the PEG polymer, 
complete removal of the PEG polymer, and conjugation of the fluorophore to different 
functional groups on the peptide and peptide-PEG molecule. The set of these bioactive 
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probes were validated using a mouse model, and it was determined that the most effective 
probe included the peptide, PEG76 polymer, and fluorophore conjugated to the PEG76 
polymer. 
  
 
Figure 1. 7 Representative image taken using NIR fluorescence imaging of mouse models 3 hours post-
injection with the bioactive probe. Normal group (a); blocking group (b) pre-injected with a non-fluorescently 
active bioactive probe before injection with bioactive probe [Adapted from Xiao, et al., 2010]. 
 
Specificity tests of the probe were performed on a mouse model. Acute 
inflammation was induced by a topical application of phorbol myristate acetate (PMA) to 
the left earlobes of the mice. This caused ear dermatitis, which ultimately promoted the 
migration of neutrophils to the afflicted area. The fluorescent bioactive probe was injected 
into the mouse model via a tail vein, and in vivo NIR fluorescence imaging was performed. 
In models injected with the probe, fluorescence intensities were recorded at higher levels 
than the control, suggesting high binding affinity for the FPRs on neutrophil cells. 
Specificity experiments were conducted as well by pre-injecting mice with a non-
fluorescent peptide one hour before injecting the specimen with the fluorescent probe. It 
was expected that the models pre-injected with blocking agents would not show high 
neutrophilic activation or accumulation under fluorescence studies if the bioactive peptide 
was selective for FPRs. Comparative analysis showed lower fluorescence intensities in the 
 
 
16 
blocking group than in the normal group (Figure 1.7), suggesting that the probe has high 
specificity for FPRs. The group concluded that a potential probe was synthesized for NIR 
fluorescence bioimaging specifically targeted towards neutrophilic activation and 
accumulation.17 This probe is available for commercial purchase.16 However, the 
attachment of only the Cy7 fluorophore limits the range of use for the tool. Bioactive probes 
such as the molecule developed for use in a mouse model that could be modified with a 
range of fluorophores would increase the versatility of the probe and widen the possibilities 
for bioimaging techniques. 
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1.5. Synthetic strategies to reproduce bioactive probe cFLFLFK-PEG76-fluorophore 
 
 
 
 
Figure 1. 8 Chemical structures of various platforms of organic fluorescing molecules. The color of each 
molecules loosely represents the color it emits.2  
 
Due to the established superiority of the zebrafish model and the heightened interest 
and importance of fluorescence bioimaging, there is a demand for the development of 
bioactive probes that can be utilized for bioimaging studies. These probes are attractive 
based on the modes in which they are endogenously introduced to the model. There is a 
movement towards developing new, novel fluorescent probes and biosensors that are a 
hybrid between organic fluorescent molecules and synthetic molecules, reflective of the 
probe developed by Xiao, et al.17 A host of different organic fluorescent molecules have 
been discovered and reported to emit a range of different colors and have become 
commonly used organic molecules in fluorescent imaging (Figure 1.8).2 The bright and 
photostable dyes with red to near-infrared (NIR) fluorescence are highly attractive choices 
for in vivo imaging in living systems because tissue is transparent in this wavelength 
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region. Cyanine dyes (Figure 1.8e) have been modified and adapted to accommodate this 
demand. Fluorescein (Figure 1.8b) and rhodamine (Figure 1.8c) are the mostly commonly 
used molecules for labelling or as probes for bioimaging.  
The fluorescein and rhodamine dyes are also analogous to the GFP and mCherry 
proteins previously discussed. These small molecules have potential to be incorporated into 
a synthetic peptide targeting FPRs and replace the need for transgenic zebrafish models 
used for studies of host-pathogen interactions in the presence of infection. Furthermore, as 
there is a wide variety of known fluorophore molecules, there is potential to create a library 
of probes that would increase the versatility of bioimaging of zebrafish models for 
infection.  
1.6 Thesis Project Overview 
 
 
 
Figure 1. 9 Structure of the target molecule of interest, cFLFLFK-PEG76-5(6)-ROX. The attached 
fluorophore is a 5(6)-ROX, a derivative of the rhodamine class. This particular derivative is analogous to that 
of the mCherry protein.  
 
 Synthesis of a bioactive probe for use in a zebrafish model to study host-pathogen 
interactions was conducted using similar methods previously discussed. The target 
molecule consisted of a bioactive peptide, PEG polymer, and small molecule fluorophore 
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(Figure 1.9). The short hexapeptide capped with a cinnamoyl, cFLFLFK, was produced 
using solid phase peptide synthesis procedures. Both manual and automated methods were 
investigated for production of the peptide. The addition of a PEG76 polymer was done 
through bioconjuation in a buffer system. The fluorophores of interest were chosen based 
on their similarities in characteristics to the current proteins encoded in transgenic zebrafish 
models. A 5(6)-ROX fluorophore was chosen as the synthetic alternative to the mCherry 
protein. It will be attached to the peptide-PEG76 complex through bioconjugation. After the 
completion of each component (peptide, peptide-PEG76, peptide-PEG76-fluorophore), 
purification was performed via high performance liquid chromatography (HPLC) and size 
exclusion chromatography. Characterization studies were performed for each molecule 
with mass spectrometry, 1H NMR, 1C NMR, and UV-vis analyses. Once the target 
molecule is completed, validation of the probe will be confirmed through application to an 
unmodified zebrafish model. 
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CHAPTER 2: EXPERIMENTAL 
2.1.  Materials and general considerations 
 
 All chemicals were available from commercial suppliers and did not undergo any 
purification or altering unless specified. For automated peptide synthesis an AAPPtec 
automated peptide synthesizer was used, and all reactions were run at room temperature 
under N2. Analytical to semi-preparative high-performance liquid chromatography 
(HPLC) was performed with a Gilson GX-271 liquid handler and a Gilson 322 pump. A 
Kintex 5 µm EVO C18 100Å 4.6 x 150 mm column and Kinetex 5 µm EVO 
 
C18 100Å 21.1 x 150 mm column were used for analytical and preparative purposes, 
respectively. Data was rendered in Trilution LC software. Products were characterized by 
1H and 13C NMR, liquid chromatography/mass spectrometry (LC/MS), matrix assisted 
laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) and UV-
vis analysis. A Varian UNITY INOVA 400 MHz instrument was used to obtain 1H and 13C 
NMR data.  An Agilent 1100 series HPLC coupled with a diode array detector (DAD, 
model G1315A) and a mass selective detector (MSD, model G2445A) operating in 
electrospray ionization (ESI) was used to collect LC/MS data. A Bruker Daltonics 
UltrafleExtreme MALDI TOFTOF instrument was utilized to collect MALDI-TOF MS 
data. A Beckman DU 7500, Diode Array UV-vis spectrophotometer was used for UV-vis 
analysis. A SpectraMax i3x UV-vis spectrophotometer was also used for UV-vis analysis.  
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2.2. Synthesis of hexapeptide, cFLFLFK-NH2, via solid phase peptide synthesis  
using manual coupling techniques 
 
 
 
 
Scheme 2. 1 Overview of synthesis of hexapeptide, cFLFLFK, with solid phase peptide synthesis using 
standard Fmoc chemistry. 
 
2.2.1. Preparation of Resin  
The target peptide, a hexapeptide, cFLFLFK-NH2, was synthesized using a 
modified procedure published by Xiao, et al13. To a polyprep column (BioRad), 0.1 g of 
Fmoc-PAL-AM resin (0.5-0.8 mmol/g, EMD Milipore) was added. To prepare the solid 
support, the resin was swelled by adding 2 mL of dry dichloromethane to the polyprep 
column and then the column was agitated in an incubator at 190 rpm and room temperature. 
After 1 hour, the dichloromethane was eluted, and the resin was washed with 2 mL of DMF 
three times.  
1 
2 
3 4 5 
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2.2.2. Removal of Fmoc protecting group  
For removal of the Fmoc group, a solution of 20% 4-methyl piperidine was prepared in an 
inert environment and stored in a flame-dried 40-mL vial. Then 8 mL of the prepared 
solution was added to the polyprep column containing the swelled resin and the column 
was agitated in an incubator at 190 rpm, at room temperature, for 1 hour. The 20% 4-methyl 
piperidine solution was then eluted, and the resin was washed with 10 mL of DMF, three 
times.  
2.2.3. Elongation of peptide  
For coupling of the first amino acid, an Fmoc-protected lysine, a coupling cocktail was 
prepared by dissolving 0.281 g of Fmoc- Lysine (0.6 mmol), 0.248 g of O-(6-
Chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU; 
0.6 mmol), and 0.157 mL of diisopropylethylamine (DIPEA; 0.9 mmol) in 1 mL of DMF. 
The solution was immediately transferred to the polyprep column, and the reaction was 
agitated in an incubator at 190 rpm, at room temperature, for 1 hour. Once complete, the 
coupling cocktail was eluted, and the resin washed with 10 mL of DMF three times. 
2.2.4. Monitoring of reaction progress via UV-vis spectroscopy   
To monitor the progress of the coupling reaction, 8 mL of DMF was added to the 
column. The column was briefly shaken, to evenly disperse resin, and then 20 µL aliquot 
of the solution was reserved and transferred to a 7 mL vial. The resin was dried under 
vacuum to remove DMF. Then 3 mL of the 20% 4-methylpiperidine was added to the vial, 
and the resin was agitated in an incubator at 190 rpm for about 20 minutes. Then a UV-vis 
reading was taken at 290 nm against a blank of 20% 4-methyl piperidine. 
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For the coupling of the subsequent amino acids, the previously described procedure 
for deprotection of the Fmoc group and the coupling of the activated amino acid was 
followed (Sections 2.2.2 and 2.2.3.). After each coupling reaction (described in section 
2.2.3), loading was monitored via UV-vis.  
2.2.5. Coupling of cinnamoyl cap 
To cap the peptide with a cinnamoyl group, the Fmoc group was first removed from the 
terminal amino acid (phenylalanine) following the previously described methodology. A 
coupling cocktail was similarly prepared by dissolving 0.089 g cinnamic acid (0.6 mmol), 
0.248 g of HCTU (0.6 mmol), and 0.157 mL of DIPEA (0.9 mmol) in 3 mL of DMF. The 
solution was immediately transferred to the polyprep column and the reaction was agitated 
in an incubator at 190 rpm, at room temperature, for 20 hours. At this point, the plastic 
polyprep column, originally clear and colorless, was stained a dark brown, and the eluent 
also a dark brown color. A pale brown colored sediment formed in the bottom of the 
column. The resin was separated from the layer of sediment by adding DCM to the column 
and collecting the top layer that formed, which contained only resin. The resin was then 
washed with 5 mL of DCM three times.  
2.3. Synthesis of peptide cFLFLK via automated synthesis 
 This procedure followed for manual coupling was adapted for synthesis of the 
peptide using an automated peptide synthesizer. In set-up for this reaction, a solution of 
20% piperidine in DMF was prepared, 0.5 M solutions of the amino acids were prepared, 
0.5 M solution of HCTU was prepared, and a 0.75 M solution of DIPEA was prepared. To 
the synthesizer 0.050 g of PAL-AM resin was added, and swelled in the peptide 
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synthesizer, in DCM for 1 hour then washed with DMF three times before deprotection 
and coupling proceeded.  
For deprotection, 2.0 mL of 20% 4-methylpiperidine was transferred to the resin, 
and the resin was incubated and shaken for 1 hour. Then the resin was washed with DMF 
3 times. Then the instrument delivered 0.7 mL of 0.5 M Fmoc-protected amino acid 
solution, 1 mL of 0.5 M HCTU, and 1 mL of 0.75 mL of DIPEA to the resin. The resin 
was incubated and shaken for 1 hour, then washed with DMF 3 times, and the deprotection 
and coupling cycles would begin for the next amino acid.  
 After the final coupling of the last phenylalanine residue, before removing the final 
Fmoc group, the resin was washed a final time and then dried under N2 on the instrument. 
The dried resin was transferred to a polyprep column, and the final deprotection and 
coupling with the cinnamic acid was carried out following manual coupling procedures. 
2.4. Cleavage of peptide from PAL-AM resin 
 
 
 
 
Scheme 2. 2 Cleavage of synthesized peptide, cFLFLFK, from solid support using an 18:1:1 solution of 
TFA, water, and triisopropylsilane.  
 
 To remove the synthesized peptide from the solid support after both manual 
coupling and automated synthesis methods, the resin was first dried under a stream of N2 
gas for 1 hour. Then a cleavage cocktail was prepared by combining 4.5 mL of TFA, 0.25 
2 6 7 
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mL of water, and 0.25 mL of triisopropylsilane (TIPS). The solution was immediately 
transferred to the polyprep column containing the loaded resin. The reaction was agitated 
in an incubator at 190 rpm, room temperature, for 1 hour. Then the solution was eluted and 
collected in a 20 mL vial. The TFA, water, and TIPS solution was removed via a rotary 
evaporator and dried under vacuum.  
 
Minutes 
 
Figure 2. 1 Analytical HPLC trace for purification of peptide cFLFLFK. Stationary phase: C18; mobile phase 
water:acetonitrile, 30-70%, over 10 minutes. UV-vis detected at 254 nm and 280 nm. The peak retained at 
4.5 minutes was collected characterization. 
 
The product was purified via high-performance liquid chromatography (HPLC). 
First analytical HPLC was performed, and UV-vis measurements were recorded at 254 nm 
and 280 nm to optimize conditions. It was determined that at 30-70% water to acetonitrile, 
over 10 minutes, the product was retained on the column for 4.5 minutes (Figure 2.1). The 
product was then purified with preparative HPLC. 
For manual coupling methods, the yield was 9 mg (9.52 µmol, 38%) of product. 
For automated synthesis methods, the yield was 5.9 mg (6.25 µmol, 25%) of product. Using 
HPLC, the retention time of cFLFLFK-NH2 was 4.5 minutes.  The compound produced 
using manual coupling procedures was characterized with LC/MS and 1H NMR and 13C 
cFLFLFK 
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NMR. The solvent used was methanol-D. The mass of the product was calculated to be 
944.5 g/mol. Results from the LC/MS showed that the product was 944.3 g/mol.  
13C NMR (101 MHz, CD3OD) δ 175.33 (s), 174.42 (s), 174.08 (s), 173.91 (s), 173.20 (s), 
172.27 (s), 168.22 (s), 141.74 (s), 137.31 (d, J = 4.7 Hz), 136.62 (s), 134.75 (s), 130.24 – 
129.66 (m), 128.32 (t, J = 55.2 Hz), 126.70 (s), 119.81 (s), 57.20 (s), 55.77 (d, J = 28.0 
Hz), 53.84 (s), 53.26 (s), 52.81 (s), 40.02 (s), 39.50 (d, J = 16.9 Hz), 36.98 (s), 36.52 (s), 
30.68 (s), 26.50 (s), 24.51 (d, J = 15.0 Hz), 22.20 (d, J = 23.5 Hz), 20.63 (d, J = 24.9 Hz). 
1H NMR (400 MHz, CD3OD) δ 8.64 – 8.55 (m, 8H), 8.64 – 8.31 (m, 36H), 8.10 (s, 5H), 
7.95 – 7.77 (m, 41H), 7.66 – 7.46 (m, 40H), 7.46 – 7.32 (m, 36H), 7.32 – 6.73 (m, 158H), 
6.72 (s, 9H), 4.87 (s, 307H), 4.44 (dd, J = 46.6, 39.2 Hz, 50H), 4.15 (dd, J = 15.3, 10.3 Hz, 
23H), 3.37 – 3.20 (m, 107H), 3.19 – 3.00 (m, 44H), 3.00 – 2.21 (m, 92H), 2.02 (s, 5H), 
1.88 (s, 9H), 1.71 (d, J = 9.6 Hz, 14H), 1.64 – 1.33 (m, 93H), 1.27 (d, J = 7.4 Hz, 13H), 
1.11 (s, 6H), 0.96 – 0.74 (m, 104H). 
2.5. Synthesis of peptide cFLFLFK-PEG76-NH2 
 
 
 
Scheme 2. 3 Conjugation of polyethylene glycol polymer (PEG76) in a 0.1 M acetonitrile sodium borate buffer 
of pH 8.5. 
6 
8 
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 For the conjugation of the polyethylene glycol molecule to the ω-NH2 of the lysine 
residue, a procedure previously published by Zhang, et al. was followed20. In a 7 mL vial, 
3.2 mg of peptide cFLFLFK-NH2 and 12.6 mg of tert-Boc-PEG-NHS (PEG76, MW-3400 
Da; Laysan Bio Inc.) was dissolved in a 1:1 mixture of acetonitrile and sodium borate 
buffer (0.1 M, pH 8.5), at 4°C or 24 hours. The reaction was monitored via analytical HPLC 
(Figure A1). The stationary phase was a C18 column and the mobile phase was 
water:acetonitrile (50-80%). Absorbance was measured at 215 nm and 254 nm. The 
product was then purified via preparative HPLC using the conditions optimized in 
analytical experiments and characterized via mass spectrometry (MALDI-TOF). The 
calculated mass of the compound was 4489.6 g/mol. The experimental mass of the 
compound was found to be 4511.9 g/mol.  
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2.6. Conjugation of fluorophore, 5(6)-ROX NHS ester 
 
 
 
Scheme 2. 4 Conjugation of 5(6)-ROX NHS ester fluorophore in a 0.1 M sodium bicarbonate buffer of pH 
8.5.  
2.6.1. Conjugate addition of 5(6)-ROX NHS ester  
For the conjugation of the 5(6)-ROX NHS ester fluorophore, an adapted protocol 
was used previously published by the manufacturer.24 In a 7-mL vial, covered completely 
in aluminum foil, 2.8 mg of 5(6)-ROX NHS ester (3.48 µmol, 8 equivalents) were dissolved 
in 1/10th of the reaction volume of DMSO (0.1 mL). In separate 7-mL vial, 1.9 mg of 
cFLFLFK-PEG76-NH3+ compound was dissolved in 9/10th of the reaction volume of 0.1 M 
sodium bicarbonate buffer (pH 8.5; 0.9 mL). The reaction was run for 12 hours at room 
temperature. The reaction was monitored via HPLC. The stationary phase was a C18 
column, and the mobile phase was water:acetonitrile (30-70%).  
9 
10 
11 
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2.6.2. Purification of cFLFLFK-PEG76-5(6)-ROX via size exclusion chromatography 
Before purification, the product was condensed using rotary evaporation until about 
0.1 mL of solvent remained. Solid precipitate formed, and 0.8 mL of distilled water was 
added to the reaction vessel to re-dissolve product. Then the product was purified using 
size exclusion chromatography on a Sephadex G-25 column. The Sephadex G-25 media 
was pre-swelled in distilled water and then packed into a 4.5 cm tall column with diameter 
2 cm. The column was equilibrated with distilled water. Then half of the solution 
containing product (about 0.5 mL) was loaded onto the column. Over and hour and a half, 
19 1-mL fractions were collected in 1.5-mL microcentrifuge tubes. The first 10 fractions 
that eluted from the column were clear and colorless. The subsequent fractions were still 
clear but were a pink hue that gradually intensified and then weakened again.  
The fractions were analyzed via UV-vis spectroscopy. A plate was prepared with 
100 µL of each fraction collected. A full absorbance spectrum was measured for each 
fraction against a blank of distilled water. Based on this analysis, fractions 4-10 and then 
fractions 11-17 were combined and condensed for further study. Instead of using a plate 
reader, the samples scanned in a quartz cuvette against a blank of distilled water. Then the 
sample containing fractions 11-17 was analyzed via mass spectrometry (MALDI-TOF 
MS). 
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CHAPTER 3: RESULTS & DISCUSSION 
 
 
 
 
 
 
Figure 3. 1 Structure of overall target molecule, cFLFLFK-PEG76-5(6)-ROX. This is a bioactive, 
fluorescently tagged peptide modified with a polyethylene glycol (PEG76) polymer. Synthesis of the 
molecule was divided into three parts. 
 
The target bioactive probe is of interest due to previous studies determining that 
this peptide has a specific binding affinity to the formyl peptide receptors found the surface 
of neutrophils in mice.17 This binding affinity provides researchers with a method to attach 
small molecules, such as fluorophores, to the neutrophils. As a result, researchers are 
enabled to visualize cellular interactions of the neutrophils at the molecular level. 
Furthermore, these fluorescent imaging studies utilizing the bioactive probe may be 
performed in vivo, as it is biologically relevant to living systems. 
 The target molecule in this study was a short hexapeptide, FLFLFK, capped with a 
cinnamoyl, that was modified with the addition of a PEG76 polymer and tagged with a 
fluorophore (Figure 3.1). The synthetic route was divided into three parts. First the peptide 
capped with the cinnamoyl was to be synthesized. This molecule was targeted based on its 
binding affinity to the formyl peptide receptors on the neutrophils in a mouse model. Then 
Part I                Part II      Part III 
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the PEG76 polymer could be conjugated to the peptide. The addition of the PEG76 molecule 
was determined to be important in increasing the bioavailability of the peptide.17 Finally, a 
fluorophore could be conjugated to the PEG76 polymer to produce the target molecule. The 
fluorophores were chosen based on their similarities in absorbance and emission 
characteristics to the fluorescent proteins currently genetically encoded in zebrafish 
models.  
3.1. Synthesis of peptide cFLFLFK 
 
 
Figure 3. 2 Structure of target molecule, peptide FLFLFK, capped with a cinnamoyl group. 
 
 A procedure modified from Zhang, et al., was followed to synthesize the short 
hexapeptide, FLFLFK (Figure 3.2). This peptide was synthesized via manual and 
automated coupling procedures. Similar conditions were used to cap the peptide with a 
cinnamoyl group.  
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3.1.1 Selection of Resin Fmoc-PAL AM 
 
 
 
                            Linker 
 
Figure 3. 3 Structure Fmoc-PAL AM resin, consisting of an Fmoc-protected linker attached to a polystyrene 
bead. 
 
For the synthesis of the peptide cFLFLFK, an Fmoc-protected PAL AM resin was 
selected (Figure 3.3). This solid support is composed of a polystyrene bead and a linker 
that attached to and extends from the bead. The use of polystyrene as the anchor for peptide 
synthesis allows for a more uniform reaction mixture because this material is porous when 
swelled. When swelled, reagents and solvents are able to pass through the pores of the 
material.  
This resin was also selected based on its linker, as it would result in a carboxamide 
at the C-terminus after cleavage from the solid support, rather than the typical carboxylate. 
The carboxamide serves as a pseudo protecting group since the amide is less likely to be 
deprotonated and form the conjugate base of the amide. The formation of the amide allows 
for selective reactivity of the terminal primary amine on the Lysine residue in later 
reactions when the polyethylene glycol polymer is attached through a conjugation reaction.  
Another important aspect in selecting a resin is its loading value. For the Fmoc-
PAL AM resin, the loading value ranges between 0.50-0.80 mmol/g. This means that for 
every gram of resin that participates in a synthesis, between 0.50 and 0.80 mmol of product 
is expected to be produced. This value ranges because, while each polystyrene bead has 
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multiple linkers attached, not every linker will load an amino acid. Furthermore, in 
subsequent coupling reactions, amino acid residues may not be loaded onto every peptide 
on the solid support. The combination of the three aspects discussed above contributed to 
the final selection of the Fmoc-PAL AM resin for this synthesis. 
 
3.1.2 Protecting Groups 
 
 
 
Figure 3. 4 Structures of the (a) fluorenylmethyloxycarbonyl (Fmoc) protecting group and (b) the tert-
butyloxycarbonyl (Boc) protecting group 
 
 A key aspect in solid phase synthesis is the use of protecting groups. In this study, 
the two that are utilized are the fluorenylmethyloxycarbonyl (Fmoc) protecting group (Fig. 
3.4a) and the tert-butyloxycarbonyl (Boc) protecting group (Fig 3.4b), which are 
considered to be orthogonal to one another. The Fmoc group is stable in acid conditions 
but becomes labile under basic conditions, while the Boc group is stable in basic conditions 
and labile in acidic conditions. The inverse relationship of the stabilities and reactivities of 
these two groups allows for control of specific functional groups throughout a reaction.  
 In this study, the Fmoc group was used to control the reactivity of the primary amine 
at the terminal end of the linker of the resin, as well as the amines of the amino acid residues 
that participate in the peptide backbone. For removal of the Fmoc group, a 20% 4-
methylpiperidine solution was used.  
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 The primary amine at the terminal end of the lysine residue side chain was of 
concern due to its reactivity and the possibility of forming impurities through side chain 
involved reactions. It could not be protected with an Fmoc group, as it was the first amino 
acid residue to be loaded onto the solid support, and the reactivity would be recovered in 
the next deprotection step. Thus, a lysine compound was selected that had an Fmoc group 
protecting the terminal amine that would participate in the peptide backbone and a Boc 
group protecting the terminal amine in the side chain of the lysine residue. Because of the 
orthogonal properties of the two protecting groups, the amine of the lysine side chain would 
remain unfunctionalized throughout synthesis of the peptide. After completion of the 
synthesis the functionality of the amine in the lysine side chain could be recovered by 
removing the Boc protecting group in a trifluoracetic acid cocktail.  
 The selection of the PAL-AM resin was also related to this idea of orthogonal 
protecting group schemes. The linker attached to the polystyrene bead is stable in basic 
conditions and becomes labile only in acidic conditions, which makes it a good support 
choice for Fmoc-chemistry synthetic routes. This provides a selective route for cleavage of 
the peptide from the resin after the completion of the synthesis. 
 
3.1.3. Fmoc deprotection conditions  
 Because the Fmoc protecting group was used to reduce nucleophilicity of the amine 
groups in the amino acid residues, a solution of 4-methylpiperidine was used for removal 
of this protecting group. The 20% 4-methyl piperidine solution was prepared in dry 
dimethylformamide (DMF). The dry DMF used was purchased, but it was also stored with 
molecular sieves to maintain dryness. This polar, aprotic solvent was chosen in order to 
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reduce the likelihood of hydrolysis of the peptide backbone occurring throughout the 
synthesis of the peptide. A lower water content in the solvent was desired for this purpose 
as well.  
A challenge with the 4-methylpiperidine solution was the rate at which the 4-
methylpiperidine compound underwent oxidation. For this reason, small quantities of 
solution were prepared at a time. For manual coupling procedures, the solution was 
prepared several times through the course of the synthesis. For automatic synthesis, the 
solution was able to be prepared for one synthesis and the remaining solution was discarded 
before the next synthesis. 
 
 
 
 
Figure 3. 5 Mechanism of removal of the Fmoc protecting group by 4-methylpiperidne to recover 
functionality of terminal amine of the peptide on solid support. 
 
 In the deprotection reaction the 4-methylpiperidine deprotonates the alpha proton, 
transforming the aromatic system in the Fmoc molecule to become a good leaving group 
(Figure 3.5). The reaction proceeds an E2 type elimination reaction, producing a byproduct 
molecule. Decarboxylation proceeds and produces CO2 gas as another byproduct. The 
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aromatic byproduct remains in the 20% 4-methylpiperidine solution and is removed when 
the deprotection solution is removed.  
In order to maintain a uniform reaction solution, the reaction vessel was incubated 
and agitated with each deprotection. Reaction times never exceeded more than one hour, 
as the possibility of the resin being degraded by the 4-methylpiperidine compound 
increased over time. The resin and reaction column were thoroughly washed after each 
deprotection treatment, in order to fully remove all 4-methylpiperidine. Even trace amounts 
of the deprotection solution could result in removal of the Fmoc group protecting 
subsequent amino acid resides. This could result in double coupling events and would 
ultimately change the peptide sequence. Consequentially, with the thorough washings, the 
Fmoc byproduct was removed after each deprotection.  
 
3.1.4. Reaction monitoring via UV-vis spectroscopy 
 
Figure 3. 6 UV-vis measurements at 290 nm of Fmoc washings after coupling cycles.  
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During synthesis via manual coupling, the loading of each amino acid fragment was 
monitored via UV-vis spectroscopy. The deprotection solution, containing the aromatic 
Fmoc byproduct formed in the deprotection scheme (Figure 3.6) was analyzed after each 
coupling reaction, as well as the deprotection to remove the Fmoc group from the resin. 
After several washing cycles, DMF washings were analyzed to determine that no Fmoc 
byproducts remained and confirm that the resin and reaction volume could be cleaned 
efficiently with DMF rinses. 
A full absorption spectrum was measured for analysis. It was expected for the 
highest absorbance to occur at 290 nm. It was also predicted that this method of monitoring 
reaction progress would provide insight into the percent of each coupling. As previously 
discussed, the loading percentage decreases after each coupling cycle. As a result, it was 
expected for intensity of absorbance to decrease at 290 nm after each coupling cycle. This 
trend, however, was not observed.  
The challenge with this method of monitoring the reaction was removing a 
consistent amount of resin for analysis after each coupling of the next amino acid. Due to 
the small amount of resin collected each time (about 1-2 mg), it was difficult to weigh the 
amount analyzed accurately and the loading percent could not be concluded from this 
method. 
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Figure 3. 7 Standardized curve measuring presence of Fmoc byproduct. 
 
 
In later trials, rather than drying the resin and attempting to record a weight, 20 µL 
aliquot of solution containing resin was removed and then dried and weighed. Then this 
sample was treated with the deprotection solution, which was collected for analysis. The 
challenge with this method was ensuring that the resin was evenly suspended in the solution 
when the sample was taken, and a consistent amount of resin still was unable to be collected 
for analysis. The absorbance values were standardized to correct for the varying amounts 
of resin that were analyzed (Figure 3.7). From the UV-vis measurements, it could be 
determined that the Fmoc deprotection was occurring at each step, however, the percent of 
coupling after each cycle could not be determined throughout the synthesis. 
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3.1.5. Coupling conditions - 
 
 
 
 
Figure 3. 8 Coupling mechanism using HCTU as coupling reagent. Hunig’s base (N,N-
diisopropylethylamine) was used as the base.  
 
= R1 
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 For the loading of subsequent amino acid residues, there were three major 
components in the coupling cocktail, which were the coupling reagent, a base, and the 
amino acid residues. The coupling reagent chosen for this synthesis was HCTU (O-(1H-6-
Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate). This 
compound was developed to have two functionalities in coupling reactions (Figure 3.8). 
First, a base is used to form the carboxylate of the amino acid residue. Hunig’s base 
(diisopropylethylamine) in excess was utilized in this synthesis for this purpose. Then the 
carboxylate performs a nucleophilic attack on the carbon of the amide bond. An ester 
intermediate forms containing the amino acid residue and the HCTU compound is 
transformed so that it contains a deprotonated hydroxyl. The coupling reagent now serves 
as the nucleophile and the carbon within the carbonyl of the ester intermediate acts at the 
electrophile. The amino acid is transferred back to the coupling reagent to form the fully 
activated amino acid residue, and tetramethyl urea is produced as a byproduct. The terminal 
amine of the peptide on solid support is able to attack the activated amino acid residue at 
the electrophile carbon of the carbonyl. A tetrahedral intermediate is formed, and the 
product that forms results in the new amino acid residue finally being attached to the 
peptide chain on the solid support. The coupling reagent fragment is produced as 
byproduct. The excess base is used to deprotonate the nitrogen in the newly formed amide 
bond, and the elongation of the peptide is complete.  
As previously discussed, in manual coupling procedures, the amino acid residue 
was activated in a coupling cocktail prepared externally from the reaction vessel containing 
the resin. For automated synthesis, the coupling cocktail was prepared within the reaction 
vessel already containing resin. In both procedures, the amino acid residues to be coupled 
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were selectively activated. During manual coupling procedures, the coupling cocktail was 
prepared immediately before the reaction was to begin, as it was learned that the activated 
amino acid has limited stability before degrading. But, because the amino acid compound 
and the coupling reagent needed to be dissolved in solvent, the solution was prepared 
externally before being transferred to the reaction vessel. 
 
3.1.6. Cleavage and Boc deprotection conditions - 
 
 
Figure 3. 9 (a) Mechanism for cleavage of peptide and (b) global deprotection of Boc protecting group 
attached to the lysine residue sidechain.  
 
 After the completion of the synthesis and capping of the peptide, it was removed 
from the solid support. A cleavage cocktail of trifluoroacetic acid (TFA), water, and 
triisopropylsilane (TIPS) was used (Figure 3.9). This cleavage cocktail also resulted in the 
global deprotection of the Boc side chain on the lysine residue. The water and TIPS 
R1 = 
= R2  
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compound were used as nucleophilic scavengers for the carbocation produced in each 
reaction.  Carbon dioxide gas was also produced as a byproduct in each of these reactions. 
The reaction solution and byproducts were removed by evaporation.  
3.1.7. Isolation and purification techniques of cFLFLFK -  
3.1.7.1. Purification of cFLFLFK via high performance liquid chromatography (HPLC) 
 For purification, the crude product was dissolved in methanol for HPLC analysis 
and purification. In several trials, the product was attempted to be dissolved in water, 
however, a gel-like substance formed. Methanol was added, and the gel partially dissolved 
and solid precipitates formed. Centrifugation and syringe filtration were used to remove 
the solid particles, and the methanol solution was injected on the analytical HPLC. It was 
hypothesized that the formation of the gel was an effect of residual TFA and base forming 
a salt. 
3.1.7.2. Isolation via cold ether precipitation 
 In one trial, after the completion of peptide synthesis, isolation of product was 
attempted using cold diethylether. It was expected for the product to crash out of solution. 
This precipitation event did not occur immediately, and the solution was left overnight at 
4°C, however no precipitates formed. It was later determined that this isolation method 
was not possible due to the nonpolar characteristics of the molecule. The modifications to 
yield C-terminus amide and the N-terminus capped with the cinnamoyl group, the product 
was highly nonpolar. The compound would not form a precipitate in the cold ether solution. 
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3.1.9. Characterization of peptide cFLFLFK 
 
 
Figure 3. 10 Chromatogram of LC/MS analysis of peptide cFLFLFK 
 
 After purification, the product was characterized via liquid chromatography/mass 
spectrometry. The product was expected to be protonated at the terminal amine of the lysine 
residue sidechain, and had an expected mass of 944.5 g/mol. Mass spectrometry results 
measured a mass of 943.7 g/mol. The slight difference (0.9 g/mol) was attributed to error 
of the instrument, and it was concluded that the product was most likely the expected 
peptide. 
 The product was further analyzed via 1H NMR and 13C NMR (Figure 3.11). In both 
spectra, various regions showed chemical shifts expected for the different characteristics 
present in the target molecule. Based on these spectra, it was further concluded that the 
desired product had been synthesized. 
 Neither of these techniques provide insight to the order of the connectivity of the 
amino acid fragments in the peptide chain. However, based on the reaction conditions and 
the low likelihood of contamination occurring among amino acid compounds, and the 
thorough washings that occurred in between each reaction step, it was concluded that the 
peptide had been produced with the desired sequence. 
 
cFLFLFK 
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(a) 
 
 
 
(b) 
 
 
Figure 3. 11 (a) 1H NMR spectrum of peptide cFLFLFK (solvent: methanol-D) and (b) 13C NMR spectrum 
of peptide cFLFLFK (solvent: methanol-D) 
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3.1.10. Summary of synthesis of peptide cFLFLFK 
 Several trials were performed to attempt to optimize reaction conditions and 
isolation and purification methods. In the case of manual coupling, the largest hurdle to 
overcome was isolating and purifying product. It was determined that purification via 
HPLC was the most efficient tool for this purpose. Smaller challenges that presented 
involved the stability window of activated amino acid fragments and the ability to monitor 
the progress of the reaction after each coupling cycle.  
 In the case of automated peptide synthesis, the largest issue had to do with the 
system software and creating reaction files to run the synthesis. Smaller technicalities 
related to the instrument also needed to be addressed before the instrument was run 
properly. Optimization of reagent concentrations was another obstacle that was 
troubleshooted for these reactions. Once these issues were resolved, the automated 
synthesis protocol proved to be the superior route for synthesizing this product. The time 
taken to produce the peptide was reduced from two weeks to about ten hours. One downside 
to this method of synthesis is the inability to monitor the reaction with each coupling cycle. 
Another downside in this synthetic route is the need to perform the final coupling with the 
cinnamoyl cap manually. However, these disadvantages are mitigated by the efficiency of 
this instrument, and the sizeable reduction of time needed to produce product. 
 
3.2. Conjugation of polyethylene glycol (PEG) polymer 
 Relative to most biomacromolecules, the peptide cFLFLFK is very hydrophobic. 
This causes the bioavailability of the molecule to decrease in living systems. The low 
bioavailability is usually due to the compound low solubility or segregation to fatty tissues, 
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rather than the intended target cells, which usually reside in relatively aqueous 
environments. To increase bioavailability, a polyethylene glycol molecule was conjugated 
to the terminal amine of the lysine residue in the peptide chain.  
3.2.1 Selection of biheterofunctionalized PEG76 moiety, tBOC-PEG76-NHS ester -  
 
 
Figure 3. 12 Structure of biheterofunctionalized tBoc-PEG76-NHS ester 
 
 A PEG polymer with an average length of 76 repeat units was selected that was 
biheterofuntionalized in order for the conjugate addition to occur selectively at the terminal 
amine of the lysine residue size chain (Figure 3.12). One end of the polymer was 
functionalized with an N-hydroxysuccinimide ester. The other end of the polymer was 
functionalized with a primary amine. The reactivity of this terminal amine was masked 
with use of a Boc protecting group. The reactivity could be later recovered after removal 
of the Boc group using a TFA cleavage cocktail. The cleavage of the Boc group proceeded 
as the mechanism described in section 3.1.6 and shown in Figure 3.9.  
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3.2.2. Reaction conditions for conjugation of tBoc-PEG76-NHS ester to cFLFLFK 
 
 
 
Figure 3. 13 Reaction mechanism for the conjugate addition of the tBoc-PEG76-NHS ester to the terminal 
amine of the lysine residue side chain. 
 
 The conjugate addition was completed in an acetonitrile sodium borate buffer 
solution of pH 8.5 over a period of 24 hours (Figure 3.13). The reaction progress was 
monitored via analytical HPLC (Figure A1). The PEG76 molecule is does not absorb light, 
which posed as a challenged in this experiment. The absorbance was measured at 254 nm 
to monitor the peptide compound. To selectively monitor the PEG76 molecule, absorbance 
was measured at 215 nm. At this wavelength, the Boc protecting group could be traced on 
the PEG76 molecule, and as the polymer was the only molecule with this protecting group, 
absorbance at this wavelength would be indicative of PEG76 only.  
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 The reaction was run in basic conditions, to control the deprotonation of the 
terminal amine of the lysine residue side chain (Figure 3.10). This transformed this amine 
into a good nucleophile, which attacked at the electrophilic carbon of the N-
hydroxysuccinimide ester. A tetrahedral intermediate formed and when it degraded, the N-
hydroxysuccinimide acted as the leaving group produced the conjugated product. 
3.2.3. Purification of cFLFLFK-PEG76-Boc via HPLC  
The product cFLFLFK-PEG76-Boc was purified via HPLC. After the conjugate 
addition of the PEG polymer, the product was able to be dissolved water. Purification was 
performed using the same methods optimized in the analytical experiments. In two trials, 
the peak collected for characterization did not have the expected retention time. In one trial, 
the peak eluted at 13.5 minutes. In another, the peak eluted at 2.5 minutes. The varying 
retention times was attributed to the loading difference between the analytical column and 
the preparatory columns. In both trials, the UV-vis data were a strong indicator for selecting 
which peaks to collect and perform characterization analyses on. 
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3.2.4. Characterization via mass spectrometry (MALDI-TOF) 
 
 
Figure 3. 14 Mass spectrometry spectrum of cFLFLFK-PEG76-Boc compound (method: MALDI-TOF) 
 
As previously discussed, a PEG76 moeity was selected, which has an average 
molecular weight of 3.4 kDa. The length of this polymer was determined in previous 
studies to increase the bioavailability of the peptide when attached. After conjugation, the 
calculated mass of the product was 4489.6 g/mol.  Due to the mass of this product, mass 
spectrometry was performed using a matrix assisted laser desorption ionization-time of 
flight (MALDI-TOF) method (Figure 3.14).  
The resulting spectrum for this analysis appeared as a bimodal distribution curve. 
The distribution nature of the curve was attributed to the factor of the PEG polymer that 
was purchased exists in a range of lengths, with an average of 76 repeat units. The average 
molecular weight of the compound (3.4 kDa) reflects this characteristic of the polymer. 
This was also confirmed by calculating the mass difference between two neighboring peaks 
on the curves. The PEG monomer has a molecular weight of 44.053 g/mol, and the mass 
Boc-PEG76-NHS 
cFLFLFK-PEG76-Boc 
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difference between neighboring peaks was calculated to be 44.05 g/mol, confirming that 
the distribution curve was a result of the varying lengths of PEG polymer.  
It was also confirmed that the bimodal distribution was a result of unconjugated 
PEG76 compounding remaining in solution with the product. The first distribution curve 
correlated to masses expected for the tBoc-PEG76-NHS ester compound. The second 
correlated to masses expected for the product. The mass resulting from the analysis was 
4511.9 g/mol, and it was found that the extra unexpected mass was caused by the addition 
of a sodium ion (MW = 23.0 g/mol). These ions could have been contributed from matrix 
or from the glassware the peptide was stored in. When the mass of the product was 
recalculated to consider the addition of a sodium ion, the expected mass was 4512.6 g/mol. 
The 0.7 g/mol difference was attributed to instrument error, and based on this analysis, it 
was concluded that the conjugate addition of the PEG76 polymer was successful.  
 
  
Figure 3. 15 Mass spectrometry spectrum of cFLFLFK-PEG76-NH2 compound (method: MALDI-TOF) 
  
H2N-PEG76-NHS 
H2N-PEG76-cFLFLFK 
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 In a second study, cleavage of the Boc protecting group was performed before 
analyzing product (Figure 3.15). A similar spectrum resulted, showing two distribution 
curves. The distribution resulting from the varying length of peptide, and the two curves 
resulting from the presence of unconjugated PEG76 compound as well as the product was 
confirmed following similar calculations. After removal of the Boc group, the expected 
mass of the compound was 4412.5 g/mol (considering the addition of a Na+ ion). The 
observed mass was 4410.9 g/mol, resulting in a 1.7 g/mol difference in this study. This 
difference was again attributed to instrument error, and it was concluded that product had 
formed and the Boc deprotection was successful. 
 
3.3. Conjugation of fluorophore 5(6)-ROX NHS ester 
 
The final component of the overall target molecule involves the attachment of a 
fluorophore. The fluorophore chosen was analogous to one of the proteins that are 
expressed in the transgenic zebrafish model. The fluorophore, 5(6)-ROX is of the 
rhodamine family, and has been modified to absorb at 580 nm and emit at 601 nm. It was 
functionalized with an NHS ester, and coupling to the terminal amine of the PEG76 
molecule proceeded similarly to the conjugate addition of the PEG76 polymer to the 
terminal amine of the lysine residue sidechain. 
3.3.1. Conjugation conditions  
A procedure published by the manufacturers of the fluorophore was adapted for 
this reaction.24 Due to the narrow window of solvents that the fluorophore is soluble in, 
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dimethyl sulfoxide (DMSO) was chosen for this reaction, as it is a polar aprotic solvent. 
Because the selected fluorophore was functionalized with an NHS ester, a buffer with a pH 
of 8.5 was selected. NHS esters are strongly reactive with primary amines in environments 
of pH 7.0-9.0. The mechanism of this reaction was similar to that of the reaction mechanism 
detailed in section 3.2.2. and shown in Figure 3.13. The reaction was monitored via HPLC 
to determine whether the starting material was being consumed (Figure A2). After 
optimization of the mobile phase so that the fluorophore had a reasonable retention time 
on the stationary phase, the retention time for both the fluorophore and the cFLFLFK-
PEG76-NH2 compound coincided at around 6 minutes. This however, was not problematic 
due to the different wavelengths the two compounds were detected at by the UV-vis 
detector. The peptide-PEG76 compound was detected at 215 nm and the fluorophore was 
detected at 575 nm. The selectivity of these two wavelengths was determined by analyzing 
two standard solutions of each compound separately. Through this study, the conjugation 
reaction could be visualized and was confirmed by retention times that were detected at 
both wavelengths. 
3.3.2. Purification of cFLFLFK-PEG76-5(6)-ROX-NHS ester 
Purification of this product was performed via size exclusion chromatography. The 
calculated mass for this product was 4928.96 g/mol. Due to the size of the compound, a 
Sephadex G-25 media was selected for the column. Before loading the compound on the 
column, the sample was first condensed via rotary evaporation. However, the low solubility 
of the fluorophore proved to be a challenge and a solid precipitate fell out of the small 
amount of solution. The sample was re-dissolved in 0.8 mL of water to total about 1 mL of 
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sample. For loading, the sample was divided in half, and only 0.5 mL of sample was loaded 
on the column at once.  
The sample was a vibrant purple color, a result from the 5(6)-ROX fluorophore. 
This allowed for visualization of the bands that formed as the sample moved through the 
Sephadex gel. Three apparent bands formed on the column. The first was very thin and a 
pale purple color. The second was thicker in height, about 4 mm, and a dark magenta color. 
The third band was much thicker, about 10 mm, and was a less vibrant magenta color. As 
the bands separated and become more defined, the loss of uniformity of the bands was 
observed. They became more wavy-looking than straight, as they neared the bottom of the 
column, it was apparent that different sections of the bands were eluting at a varying rates. 
It was hypothesized that this lack of uniformity in the appearance of the bands may have 
been caused because such a small sample was loaded making it difficult to load it evenly 
over the entire surface of the gel. 
Based on the principles of size exclusion chromatography, however, it was still 
expected for the largest molecules to elute from the column first, while the smaller particles 
would retain on the column longer respective to their size. A total of 19 fractions were 
collected in 1-mL aliquots and reserved for analysis to confirm the order of elution. 
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3.3.3. Characterization via UV-vis spectroscopy -  
 
 
 
 
Figure 3. 16 UV-vis analysis of fractions from purification of cFLFLFK-PEG76-5(6)-ROX compound via 
size exclusion chromatography. Figure (a) shows the full spectrum absorbance scan per fraction and Figure 
(b) shows comparison of fractions that absorbed at 290 nm and fractions that absorbed at 580 nm. 
 
 The 19 fractions were all analyzed using UV-vis spectroscopy. First, specific 
wavelength scans taken of the samples. Absorbance was measured at 254 nm to determine 
whether the peptide containing compound was present. This wavelength was chosen for 
the UV-vis active aromatic side chain in the phenylalanine residues. To detect the presence 
of the fluorophore, absorbance was measured at 580 nm. Results of these scans were 
inconclusive and did not reflect the presence of either compound.  
Full spectrum absorbance scans measured from 230 nm to 1000 nm were then taken 
of all samples. The results of these scans showed high absorbance at 290 nm and 580 nm 
in fractions 11-17 (Figure 3.16). It was determined that the absorbance at 580 was 
comparable to the absorbance first predicted for the fluorophore (575 nm) and was most 
likely reflective of the presence of fluorophore. It was hypothesized that the higher 
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absorbance at 290 nm was an effect of the material the samples were scanned in. The multi-
well plate was composed of polystyrene, which absorbs in the range of 230 nm to 280 nm. 
This hypothesis was supported by the data from the UV-vis scans, which had consistently 
recorded a zero value for all fractions in the 230 nm to 280 nm range.  
Despite the lack of absorbance between 230 nm and 280 nm, these UV-vis analyses 
still provided information on the composition of the fractions. The wavelengths 290 nm 
and 580 nm were selected for the comparison of the nineteen fractions, which is illustrated 
in Figure 3.13b. Fractions 1-10 showed absorbance at 290 nm. The intensity was low, but 
was expected as a very low amount of starting material was used in this conjugation 
reaction. Furthermore, only half of the sample was loaded on the column for purification. 
Fractions 11-17 showed absorbance at both wavelengths, which suggested the presence of 
both peptide-PEG76 compound and the fluorophore. Based on this comparison, fractions 4-
10 and then fractions 11-17 were condensed for further analysis. 
 
Figure 3. 17 UV-vis analysis of (a) sample containing fractions 4-10 and (b) sample containing fractions 11-
17. 
 
-0.5 
0
0.5
1
1.5
2
2.5
3
23
0
26
0
29
0
32
0
35
0
38
0
41
0
44
0
47
0
50
0
53
0
56
0
59
0
62
0
65
0
68
0
71
0
74
0
77
0
80
0
83
0
86
0
89
0
92
0
95
0
98
0
A
b
so
rb
a
nc
e
Wavelength (nm)
UV-vis analysis of fraction samples
Fractions 4-10 Fractions 11-17
 
 
56 
 To avoid the absorbance issues at wavelength 254 nm caused by the material of the 
plate used in the first UV-vis study, the two samples containing fractions 4-10 and 11-17 
were measured in a quartz cuvette. The sample containing fractions 4-10 showed no 
absorbance at neither 254 nm nor 580 nm (Figure 3.a) However, the sample containing 
fractions 11-17 showed absorbance at both the target wavelengths. This was suggestive of 
the presence of both compound as well as the fluorophore. The disadvantage to this analysis 
however, is its limitation in providing detail in regard to connectivity of the two molecule. 
The presence of absorbance at both wavelengths cannot confirm that the conjugation 
reaction was successful. As a result, this sample will need further analysis to determine 
whether the two molecules underwent reaction and product was produced.  
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CHAPTER 4: CONCLUSION AND FUTURE WORK 
 The goal of this project was to synthesize a bioactive fluorescently active probe that 
would serve as a synthetic replacement for the use of a transgenic zebrafish model in host-
pathogen interaction fluorescence studies. In this study, the production of the bioactive 
peptide, cFLFLFK, and production of the peptide-PEG76 compound was completed 
successfully. The peptide was synthesized using manual and automated coupling 
procedures. The PEG76 polymer was attached to the terminal amine of the lysine residue 
side chain via a conjugative addition in a buffer system. The synthesis of these two 
molecules was confirmed through 1H NMR and 13C NMR and mass spectrometry analyses.  
A third molecule, the peptide-PEG76-fluorophore compound was synthesized using 
a 5(6)-ROX fluorophore through a conjugative addition in a buffer system. This third 
molecule was purified via size exclusion chromatography, and characterization 
experiments were performed with UV-vis analysis. However, further characterizations 
tests must be conducted to confirm product, such as mass spectrometry. If product is not 
confirmed, another goal will be to explore other reaction conditions for this final 
conjugation. 
 Once final product is confirmed, future work should include the validation of the 
product in a zebrafish model. Upon validation, if the proposed synthetic route in this project 
is approved, other small molecule fluorophores may begin to be considered to serve as 
modifications to the probe.  
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Appendix A 
HPLC experiments to monitor coupling of peptide and tBoc-PEG76 compound 
 
 
Figure A 1 HPLC analysis of conjugate addition reaction of tBoc-PEG76-NHS ester. 
(stationary phase: C18; mobile phase: water:acetonitrile, 50-80%, 10 minutes, UV-vis 
detection at 215 nm [red] and 254 nm [purple]) 
Table A. 1 HPLC experiments monitoring PEG76 conjugation 
Time (hr) Trace 
0 a 
1 b 
3 c 
4 d 
24 e 
  
e 
d 
c 
b 
a
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Appendix B 
HPLC experiments monitoring coupling of cFLFLFK-PEG76 and 5(6)-ROX NHS ester 
 
 
 
Figure A 2 HPLC analysis of conjugate addition reaction of the fluorophore 5(6)-ROX-
NHS ester 
Table A. 2 HPLC experiments monitoring fluorophore conjugation 
Time Sample 254 nm 575 nm 
5(6)-ROX NHS ester in 
water 
a Purple Blue 
cFLFLFK-PEG-NH2 in 
water 
b Dark blue Light blue 
0 c Blue Pink 
0.5 d Blue Pink 
1 e Blue Pink 
3 f Blue Pink 
4 g Blue Pink 
20 h Blue Pink 
  
h 
g 
f 
e 
d 
c 
b 
a
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Appendix C 
ChemFile for synthesis of peptide FLFLFK via automated coupling procedures 
 
16:52:01.56  Starting ChemFile - C:\AAPPTEC\SNI144.CHM 
16:52:01.94  1 REM ** This is the data for cycle 1. ** SynthPos=1 
16:52:02.27  2 <Set Active> SynthPos=2 
16:52:03.75  3 Goto ChemFile swell2.cht, line 1 SynthPos=3 
16:52:05.07  1 REM SWELL THE RESIN SynthPos=4 
16:52:05.40  2 Mix "RV48"  for 60.00 minutes  at 600 rpm(s) and wait. SynthPos=5 
16:52:08.75  Mixer 0 on at 600 rpm 
17:52:12.03  Mixer 0 off 
17:52:12.36  3 Empty RV48 for 2.000 minute(s) SynthPos=6 
17:54:10.45  4 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=7 
17:54:41.48  Washing with DMF (A) 3.00ml per vessel to RV48 
17:54:51.42  5 Mix "RV48"  for 5.00 minutes  at 450 rpm(s) and wait. SynthPos=8 
17:54:53.18  Mixer 0 on at 450 rpm 
17:59:55.32  Mixer 0 off 
17:59:55.71  6 Empty RV48 for 1.000 minute(s) SynthPos=9 
18:00:53.44  7 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=10 
18:00:53.60  Washing with DMF (A) 3.00ml per vessel to RV48 
18:01:03.49  8 Mix "RV48"  for 20.00 minutes  at 450 rpm(s) and wait. SynthPos=11 
18:01:05.30  Mixer 0 on at 450 rpm 
18:21:07.18  Mixer 0 off 
18:21:07.56  9 Empty RV48 for 1.000 minute(s) SynthPos=12 
18:22:05.46  10 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=13 
18:22:05.62  Washing with DMF (A) 3.00ml per vessel to RV48 
18:22:15.51  11 Return SynthPos=14 
18:22:15.89  4 Goto ChemFile depro48.cht, line 1 SynthPos=15 
18:22:17.21  1 REM FMOC DEPROTECTION SynthPos=16 
18:22:17.54  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=17 
18:22:17.59  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
18:22:17.59  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
18:22:19.52  Pick up 9000 microL and 0 steps 
18:22:28.69  A2700R 
18:22:38.69  Pick up 9000 microL and 0 steps 
18:22:47.91  A2700R 
18:23:07.25  Pick up 110 microL and 0 steps 
18:23:07.96  A33R 
18:23:08.35  Dispense 99 microL and 0 steps 
18:23:08.35  A30R 
18:23:11.20  --Cleaned Probe with 18000µl of DMF (1) 
18:23:11.97  Pick up 110 microL and 0 steps 
18:23:12.41  A33R 
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18:23:12.74  Dispense 99 microL and 0 steps 
18:23:12.74  A30R 
18:23:18.73  Pick up 2225 microL and 0 steps 
18:23:25.43  A668R 
18:23:29.22  Dispense 2126 microL and 0 steps 
18:23:29.22  A638R 
18:23:35.53  --Aspirated 2001µl from Pip-350mL[1](PIP) 
18:23:37.73  Dispense 126 microL and 0 steps 
18:23:37.73  A38R 
18:23:44.93  --Dispensed 2000µl to RV48[11] 
18:23:45.31  Dispense 1 microL and 0 steps 
18:23:45.31  A0R 
18:23:49.65  --Dispensed 126µl to RV48[11] 
18:23:52.94  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=18 
18:23:54.70  Mixer 0 on at 450 rpm 
18:26:55.68  Mixer 0 off 
18:26:56.07  4 Empty RV48 for 1.500 minute(s) SynthPos=19 
18:28:24.44  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=20 
18:28:24.44  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
18:28:24.44  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
18:28:25.16  Pick up 110 microL and 0 steps 
18:28:25.92  A33R 
18:28:26.25  Dispense 99 microL and 0 steps 
18:28:26.25  A30R 
18:28:32.24  Pick up 2225 microL and 0 steps 
18:28:38.94  A668R 
18:28:42.73  Dispense 2126 microL and 0 steps 
18:28:42.73  A638R 
18:28:48.83  --Aspirated 2001µl from Pip-350mL[1](PIP) 
18:28:51.08  Dispense 126 microL and 0 steps 
18:28:51.08  A38R 
18:28:58.22  --Dispensed 2000µl to RV48[11] 
18:28:58.66  Dispense 1 microL and 0 steps 
18:28:58.66  A0R 
18:29:02.94  --Dispensed 126µl to RV48[11] 
18:29:06.24  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=21 
18:29:08.05  Mixer 0 on at 450 rpm 
18:37:10.74  Mixer 0 off 
18:37:11.07  7 Empty RV48 for 1.500 minute(s) SynthPos=22 
18:38:39.44  8 Return SynthPos=23 
18:38:39.77  5 Goto ChemFile washdp48.cht, line 1 SynthPos=24 
18:38:41.09  1 REM Wash after Deprotection SynthPos=25 
18:38:41.47  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=26 
18:39:12.51  Washing with DMF (B) 3.00ml per vessel to RV48 
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18:39:22.45  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=27 
18:39:24.21  Mixer 0 on at 450 rpm 
18:40:26.16  Mixer 0 off 
18:40:26.49  4 Empty RV48 for 1.500 minute(s) SynthPos=28 
18:41:54.48  5 Repeat from step 2, 3 times SynthPos=29 
18:41:55.80  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=30 
18:41:55.97  Washing with DMF (B) 3.00ml per vessel to RV48 
18:42:05.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=31 
18:42:07.66  Mixer 0 on at 450 rpm 
18:43:09.24  Mixer 0 off 
18:43:09.57  4 Empty RV48 for 1.500 minute(s) SynthPos=32 
18:44:37.45  5 Repeat from step 2, 3 times SynthPos=33 
18:44:38.76  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=34 
18:44:38.93  Washing with DMF (B) 3.00ml per vessel to RV48 
18:44:48.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=35 
18:44:50.63  Mixer 0 on at 450 rpm 
18:45:53.24  Mixer 0 off 
18:45:53.57  4 Empty RV48 for 1.500 minute(s) SynthPos=36 
18:47:21.45  5 Repeat from step 2, 3 times SynthPos=37 
18:47:22.77  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=38 
18:47:22.94  Washing with DMF (B) 3.00ml per vessel to RV48 
18:47:32.82  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=39 
18:47:34.64  Mixer 0 on at 450 rpm 
18:48:36.70  Mixer 0 off 
18:48:37.03  4 Empty RV48 for 1.500 minute(s) SynthPos=40 
18:50:05.46  5 Repeat from step 2, 3 times SynthPos=41 
18:50:06.78  6 Return SynthPos=42 
18:50:07.16  6 REM HBTU48 SynthPos=43 
18:50:07.49  7 Dispense Sequence SNI141.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=44 
18:50:07.49  Dispensing from Rack 4x7 vessel 11 to Rack RV48 vessel 11 
18:50:09.42  Pick up 4000 microL and 0 steps 
18:50:13.65  A1200R 
18:50:27.93  Pick up 110 microL and 0 steps 
18:50:28.69  A33R 
18:50:29.02  Dispense 99 microL and 0 steps 
18:50:29.02  A30R 
18:50:31.94  --Cleaned Probe with 4000µl of DMF (1) 
18:50:32.65  Pick up 110 microL and 0 steps 
18:50:33.03  A33R 
18:50:33.36  Dispense 99 microL and 0 steps 
18:50:33.36  A30R 
18:50:38.91  Pick up 924 microL and 0 steps 
18:50:41.66  A277R 
18:50:45.34  Dispense 823 microL and 0 steps 
18:50:45.34  A247R 
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18:50:51.43  --Aspirated 698µl from 4x7[11](Lys(Boc)) 
18:50:53.47  Dispense 0 microL and 0 steps 
18:50:53.47  A0R 
18:50:58.85  --Dispensed 823µl to RV48[11] 
18:51:02.09  8 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=45 
18:51:02.09  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
18:51:02.09  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
18:51:04.01  Pick up 2250 microL and 0 steps 
18:51:06.43  A675R 
18:51:19.01  Pick up 110 microL and 0 steps 
18:51:19.78  A33R 
18:51:20.11  Dispense 99 microL and 0 steps 
18:51:20.11  A30R 
18:51:23.02  --Cleaned Probe with 2250µl of DMF (1) 
18:51:23.73  Pick up 110 microL and 0 steps 
18:51:24.11  A33R 
18:51:24.44  Dispense 99 microL and 0 steps 
18:51:24.44  A30R 
18:51:30.93  Pick up 924 microL and 0 steps 
18:51:33.67  A277R 
18:51:37.52  Dispense 823 microL and 0 steps 
18:51:37.52  A247R 
18:51:43.83  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
18:51:46.03  Dispense 124 microL and 0 steps 
18:51:46.03  A37R 
18:51:51.25  --Dispensed 700µl to RV48[11] 
18:51:51.69  Dispense 0 microL and 0 steps 
18:51:51.69  A0R 
18:51:56.03  --Dispensed 123µl to RV48[11] 
18:51:59.32  9 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=46 
18:51:59.32  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
18:51:59.32  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
18:52:01.19  Pick up 2250 microL and 0 steps 
18:52:03.66  A675R 
18:52:16.18  Pick up 110 microL and 0 steps 
18:52:16.95  A33R 
18:52:17.28  Dispense 99 microL and 0 steps 
18:52:17.28  A30R 
18:52:20.19  --Cleaned Probe with 2250µl of DMF (1) 
18:52:20.85  Pick up 110 microL and 0 steps 
18:52:21.29  A33R 
18:52:21.62  Dispense 99 microL and 0 steps 
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18:52:21.62  A30R 
18:52:27.83  Pick up 924 microL and 0 steps 
18:52:30.63  A277R 
18:52:34.47  Dispense 823 microL and 0 steps 
18:52:34.47  A247R 
18:52:40.79  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
18:52:43.04  Dispense 124 microL and 0 steps 
18:52:43.04  A37R 
18:52:48.21  --Dispensed 700µl to RV48[11] 
18:52:48.65  Dispense 0 microL and 0 steps 
18:52:48.65  A0R 
18:52:52.93  --Dispensed 123µl to RV48[11] 
18:52:56.22  10 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=47 
18:52:58.04  Mixer 0 on at 450 rpm 
19:38:00.43  Mixer 0 off 
19:38:00.76  11 Empty RV48 for 1.500 minute(s) SynthPos=48 
19:39:28.47  12 Goto ChemFile washcp48.cht, line 1 SynthPos=49 
19:39:29.79  1 REM Wash after Coupling SynthPos=50 
19:39:30.17  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=51 
19:40:01.21  Washing with DMF (A) 3.00ml per vessel to RV48 
19:40:11.09  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=52 
19:40:12.91  Mixer 0 on at 450 rpm 
19:41:14.26  Mixer 0 off 
19:41:14.64  4 Empty RV48 for 1.500 minute(s) SynthPos=53 
19:42:42.47  5 Repeat from step 2, 3 times SynthPos=54 
19:42:43.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=55 
19:42:43.95  Washing with DMF (A) 3.00ml per vessel to RV48 
19:42:53.89  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=56 
19:42:55.65  Mixer 0 on at 450 rpm 
19:43:58.10  Mixer 0 off 
19:43:58.43  4 Empty RV48 for 1.500 minute(s) SynthPos=57 
19:45:26.48  5 Repeat from step 2, 3 times SynthPos=58 
19:45:27.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=59 
19:45:27.96  Washing with DMF (A) 3.00ml per vessel to RV48 
19:45:37.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=60 
19:45:39.66  Mixer 0 on at 450 rpm 
19:46:41.07  Mixer 0 off 
19:46:41.39  4 Empty RV48 for 1.500 minute(s) SynthPos=61 
19:48:09.44  5 Repeat from step 2, 3 times SynthPos=62 
19:48:10.76  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=63 
19:48:10.92  Washing with DMF (A) 3.00ml per vessel to RV48 
19:48:20.86  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=64 
19:48:22.62  Mixer 0 on at 450 rpm 
19:49:24.58  Mixer 0 off 
19:49:24.91  4 Empty RV48 for 1.500 minute(s) SynthPos=65 
19:50:53.45  5 Repeat from step 2, 3 times SynthPos=66 
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19:50:54.77  6 Return SynthPos=67 
19:50:55.15  13 REM ** This is the data for cycle 2. ** SynthPos=68 
19:50:55.86  14 <Set Active> SynthPos=69 
19:50:57.35  15 Goto ChemFile depro48.cht, line 1 SynthPos=70 
19:50:58.67  1 REM FMOC DEPROTECTION SynthPos=71 
19:50:59.05  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=72 
19:50:59.05  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
19:50:59.05  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
19:51:00.97  Pick up 2250 microL and 0 steps 
19:51:03.39  A675R 
19:51:15.91  Pick up 110 microL and 0 steps 
19:51:16.68  A33R 
19:51:17.07  Dispense 99 microL and 0 steps 
19:51:17.07  A30R 
19:51:19.92  --Cleaned Probe with 2250µl of DMF (1) 
19:51:20.64  Pick up 110 microL and 0 steps 
19:51:21.02  A33R 
19:51:21.41  Dispense 99 microL and 0 steps 
19:51:21.41  A30R 
19:51:27.34  Pick up 2225 microL and 0 steps 
19:51:34.09  A668R 
19:51:37.88  Dispense 2126 microL and 0 steps 
19:51:37.88  A638R 
19:51:44.20  --Aspirated 2001µl from Pip-350mL[1](PIP) 
19:51:46.40  Dispense 126 microL and 0 steps 
19:51:46.40  A38R 
19:51:53.59  --Dispensed 2000µl to RV48[11] 
19:51:53.98  Dispense 1 microL and 0 steps 
19:51:53.98  A0R 
19:51:58.31  --Dispensed 126µl to RV48[11] 
19:52:01.61  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=73 
19:52:03.37  Mixer 0 on at 450 rpm 
19:55:05.01  Mixer 0 off 
19:55:05.34  4 Empty RV48 for 1.500 minute(s) SynthPos=74 
19:56:33.44  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=75 
19:56:33.44  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
19:56:33.44  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
19:56:34.15  Pick up 110 microL and 0 steps 
19:56:34.86  A33R 
19:56:35.25  Dispense 99 microL and 0 steps 
19:56:35.25  A30R 
19:56:41.24  Pick up 2225 microL and 0 steps 
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19:56:47.94  A668R 
19:56:51.78  Dispense 2126 microL and 0 steps 
19:56:51.78  A638R 
19:56:57.88  --Aspirated 2001µl from Pip-350mL[1](PIP) 
19:57:00.13  Dispense 126 microL and 0 steps 
19:57:00.13  A38R 
19:57:07.27  --Dispensed 2000µl to RV48[11] 
19:57:07.66  Dispense 1 microL and 0 steps 
19:57:07.66  A0R 
19:57:11.99  --Dispensed 126µl to RV48[11] 
19:57:15.29  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=76 
19:57:17.05  Mixer 0 on at 450 rpm 
20:05:19.62  Mixer 0 off 
20:05:19.95  7 Empty RV48 for 1.500 minute(s) SynthPos=77 
20:06:48.44  8 Return SynthPos=78 
20:06:48.77  16 Goto ChemFile washdp48.cht, line 1 SynthPos=79 
20:06:50.14  1 REM Wash after Deprotection SynthPos=80 
20:06:50.47  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=81 
20:07:21.50  Washing with DMF (B) 3.00ml per vessel to RV48 
20:07:31.44  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=82 
20:07:33.20  Mixer 0 on at 450 rpm 
20:08:35.32  Mixer 0 off 
20:08:35.65  4 Empty RV48 for 1.500 minute(s) SynthPos=83 
20:10:03.48  5 Repeat from step 2, 3 times SynthPos=84 
20:10:04.80  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=85 
20:10:04.96  Washing with DMF (B) 3.00ml per vessel to RV48 
20:10:14.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=86 
20:10:16.66  Mixer 0 on at 450 rpm 
20:11:18.73  Mixer 0 off 
20:11:19.11  4 Empty RV48 for 1.500 minute(s) SynthPos=87 
20:12:47.49  5 Repeat from step 2, 3 times SynthPos=88 
20:12:48.80  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=89 
20:12:48.97  Washing with DMF (B) 3.00ml per vessel to RV48 
20:12:58.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=90 
20:13:00.67  Mixer 0 on at 450 rpm 
20:14:02.07  Mixer 0 off 
20:14:02.46  4 Empty RV48 for 1.500 minute(s) SynthPos=91 
20:15:30.45  5 Repeat from step 2, 3 times SynthPos=92 
20:15:31.77  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=93 
20:15:31.93  Washing with DMF (B) 3.00ml per vessel to RV48 
20:15:41.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=94 
20:15:43.63  Mixer 0 on at 450 rpm 
20:16:46.08  Mixer 0 off 
20:16:46.47  4 Empty RV48 for 1.500 minute(s) SynthPos=95 
20:18:14.46  5 Repeat from step 2, 3 times SynthPos=96 
20:18:15.78  6 Return SynthPos=97 
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20:18:16.16  17 REM HBTU48 SynthPos=98 
20:18:16.49  18 Dispense Sequence SNI142.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=99 
20:18:16.49  Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11 
20:18:18.36  Pick up 4000 microL and 0 steps 
20:18:22.59  A1200R 
20:18:36.92  Pick up 110 microL and 0 steps 
20:18:37.64  A33R 
20:18:38.02  Dispense 99 microL and 0 steps 
20:18:38.02  A30R 
20:18:40.88  --Cleaned Probe with 4000µl of DMF (1) 
20:18:41.59  Pick up 110 microL and 0 steps 
20:18:41.97  A33R 
20:18:42.30  Dispense 99 microL and 0 steps 
20:18:42.30  A30R 
20:18:47.91  Pick up 924 microL and 0 steps 
20:18:50.71  A277R 
20:18:54.33  Dispense 823 microL and 0 steps 
20:18:54.33  A247R 
20:19:00.48  --Aspirated 698µl from 4x7[13](Phe) 
20:19:02.35  Dispense 0 microL and 0 steps 
20:19:02.35  A0R 
20:19:07.73  --Dispensed 823µl to RV48[11] 
20:19:11.03  19 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=100 
20:19:11.03  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
20:19:11.03  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
20:19:12.95  Pick up 2250 microL and 0 steps 
20:19:15.37  A675R 
20:19:27.95  Pick up 110 microL and 0 steps 
20:19:28.66  A33R 
20:19:29.05  Dispense 99 microL and 0 steps 
20:19:29.05  A30R 
20:19:31.90  --Cleaned Probe with 2250µl of DMF (1) 
20:19:32.62  Pick up 110 microL and 0 steps 
20:19:33.00  A33R 
20:19:33.38  Dispense 99 microL and 0 steps 
20:19:33.38  A30R 
20:19:39.81  Pick up 924 microL and 0 steps 
20:19:42.61  A277R 
20:19:46.40  Dispense 823 microL and 0 steps 
20:19:46.40  A247R 
20:19:52.72  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
20:19:54.97  Dispense 124 microL and 0 steps 
20:19:54.97  A37R 
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20:20:00.19  --Dispensed 700µl to RV48[11] 
20:20:00.57  Dispense 0 microL and 0 steps 
20:20:00.57  A0R 
20:20:04.91  --Dispensed 123µl to RV48[11] 
20:20:08.21  20 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=101 
20:20:08.21  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
20:20:08.21  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
20:20:10.13  Pick up 2250 microL and 0 steps 
20:20:12.55  A675R 
20:20:25.12  Pick up 110 microL and 0 steps 
20:20:25.89  A33R 
20:20:26.22  Dispense 99 microL and 0 steps 
20:20:26.22  A30R 
20:20:29.24  --Cleaned Probe with 2250µl of DMF (1) 
20:20:29.96  Pick up 110 microL and 0 steps 
20:20:30.40  A33R 
20:20:30.73  Dispense 99 microL and 0 steps 
20:20:30.73  A30R 
20:20:36.93  Pick up 924 microL and 0 steps 
20:20:39.73  A277R 
20:20:43.52  Dispense 823 microL and 0 steps 
20:20:43.52  A247R 
20:20:49.84  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
20:20:52.09  Dispense 124 microL and 0 steps 
20:20:52.09  A37R 
20:20:57.31  --Dispensed 700µl to RV48[11] 
20:20:57.70  Dispense 0 microL and 0 steps 
20:20:57.70  A0R 
20:21:02.03  --Dispensed 123µl to RV48[11] 
20:21:05.28  21 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=102 
20:21:07.09  Mixer 0 on at 450 rpm 
21:06:08.98  Mixer 0 off 
21:06:09.31  22 Empty RV48 for 1.500 minute(s) SynthPos=103 
21:07:37.47  23 Goto ChemFile washcp48.cht, line 1 SynthPos=104 
21:07:38.79  1 REM Wash after Coupling SynthPos=105 
21:07:39.17  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=106 
21:08:10.20  Washing with DMF (A) 3.00ml per vessel to RV48 
21:08:20.09  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=107 
21:08:21.90  Mixer 0 on at 450 rpm 
21:09:23.69  Mixer 0 off 
21:09:24.02  4 Empty RV48 for 1.500 minute(s) SynthPos=108 
21:10:52.45  5 Repeat from step 2, 3 times SynthPos=109 
21:10:53.77  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=110 
21:10:53.94  Washing with DMF (A) 3.00ml per vessel to RV48 
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21:11:03.88  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=111 
21:11:05.64  Mixer 0 on at 450 rpm 
21:12:07.43  Mixer 0 off 
21:12:07.76  4 Empty RV48 for 1.500 minute(s) SynthPos=112 
21:13:35.47  5 Repeat from step 2, 3 times SynthPos=113 
21:13:36.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=114 
21:13:36.95  Washing with DMF (A) 3.00ml per vessel to RV48 
21:13:46.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=115 
21:13:48.65  Mixer 0 on at 450 rpm 
21:14:51.27  Mixer 0 off 
21:14:51.60  4 Empty RV48 for 1.500 minute(s) SynthPos=116 
21:16:19.48  5 Repeat from step 2, 3 times SynthPos=117 
21:16:20.80  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=118 
21:16:20.96  Washing with DMF (A) 3.00ml per vessel to RV48 
21:16:30.85  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=119 
21:16:32.66  Mixer 0 on at 450 rpm 
21:17:34.84  Mixer 0 off 
21:17:35.22  4 Empty RV48 for 1.500 minute(s) SynthPos=120 
21:19:03.49  5 Repeat from step 2, 3 times SynthPos=121 
21:19:04.81  6 Return SynthPos=122 
21:19:05.19  24 REM ** This is the data for cycle 3. ** SynthPos=123 
21:19:05.52  25 <Set Active> SynthPos=124 
21:19:07.00  26 Goto ChemFile depro48.cht, line 1 SynthPos=125 
21:19:08.32  1 REM FMOC DEPROTECTION SynthPos=126 
21:19:08.70  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=127 
21:19:08.70  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
21:19:08.70  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
21:19:10.57  Pick up 2250 microL and 0 steps 
21:19:13.04  A675R 
21:19:25.57  Pick up 110 microL and 0 steps 
21:19:26.34  A33R 
21:19:26.72  Dispense 99 microL and 0 steps 
21:19:26.72  A30R 
21:19:29.58  --Cleaned Probe with 2250µl of DMF (1) 
21:19:30.29  Pick up 110 microL and 0 steps 
21:19:30.68  A33R 
21:19:31.06  Dispense 99 microL and 0 steps 
21:19:31.06  A30R 
21:19:36.99  Pick up 2225 microL and 0 steps 
21:19:43.69  A668R 
21:19:47.54  Dispense 2126 microL and 0 steps 
21:19:47.54  A638R 
21:19:53.85  --Aspirated 2001µl from Pip-350mL[1](PIP) 
21:19:56.05  Dispense 126 microL and 0 steps 
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21:19:56.05  A38R 
21:20:03.19  --Dispensed 2000µl to RV48[11] 
21:20:03.63  Dispense 1 microL and 0 steps 
21:20:03.63  A0R 
21:20:07.91  --Dispensed 126µl to RV48[11] 
21:20:11.21  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=128 
21:20:13.02  Mixer 0 on at 450 rpm 
21:23:14.88  Mixer 0 off 
21:23:15.21  4 Empty RV48 for 1.500 minute(s) SynthPos=129 
21:24:43.48  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=130 
21:24:43.48  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
21:24:43.48  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
21:24:44.19  Pick up 110 microL and 0 steps 
21:24:44.96  A33R 
21:24:45.29  Dispense 99 microL and 0 steps 
21:24:45.29  A30R 
21:24:51.28  Pick up 2225 microL and 0 steps 
21:24:58.03  A668R 
21:25:01.82  Dispense 2126 microL and 0 steps 
21:25:01.82  A638R 
21:25:07.92  --Aspirated 2001µl from Pip-350mL[1](PIP) 
21:25:10.17  Dispense 126 microL and 0 steps 
21:25:10.17  A38R 
21:25:17.31  --Dispensed 2000µl to RV48[11] 
21:25:17.69  Dispense 1 microL and 0 steps 
21:25:17.69  A0R 
21:25:22.03  --Dispensed 126µl to RV48[11] 
21:25:25.33  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=131 
21:25:27.09  Mixer 0 on at 450 rpm 
21:33:29.50  Mixer 0 off 
21:33:29.83  7 Empty RV48 for 1.500 minute(s) SynthPos=132 
21:34:57.49  8 Return SynthPos=133 
21:34:57.82  27 Goto ChemFile washdp48.cht, line 1 SynthPos=134 
21:34:59.19  1 REM Wash after Deprotection SynthPos=135 
21:34:59.52  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=136 
21:35:30.55  Washing with DMF (B) 3.00ml per vessel to RV48 
21:35:40.44  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=137 
21:35:42.25  Mixer 0 on at 450 rpm 
21:36:43.93  Mixer 0 off 
21:36:44.26  4 Empty RV48 for 1.500 minute(s) SynthPos=138 
21:38:12.47  5 Repeat from step 2, 3 times SynthPos=139 
21:38:13.79  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=140 
21:38:13.96  Washing with DMF (B) 3.00ml per vessel to RV48 
21:38:23.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=141 
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21:38:25.66  Mixer 0 on at 450 rpm 
21:39:27.72  Mixer 0 off 
21:39:28.05  4 Empty RV48 for 1.500 minute(s) SynthPos=142 
21:40:56.48  5 Repeat from step 2, 3 times SynthPos=143 
21:40:57.80  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=144 
21:40:57.96  Washing with DMF (B) 3.00ml per vessel to RV48 
21:41:07.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=145 
21:41:09.66  Mixer 0 on at 450 rpm 
21:42:11.18  Mixer 0 off 
21:42:11.56  4 Empty RV48 for 1.500 minute(s) SynthPos=146 
21:43:39.44  5 Repeat from step 2, 3 times SynthPos=147 
21:43:40.76  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=148 
21:43:40.93  Washing with DMF (B) 3.00ml per vessel to RV48 
21:43:50.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=149 
21:43:52.63  Mixer 0 on at 450 rpm 
21:44:54.03  Mixer 0 off 
21:44:54.36  4 Empty RV48 for 1.500 minute(s) SynthPos=150 
21:46:22.46  5 Repeat from step 2, 3 times SynthPos=151 
21:46:23.78  6 Return SynthPos=152 
21:46:24.17  28 REM HBTU48 SynthPos=153 
21:46:24.50  29 Dispense Sequence SNI143.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=154 
21:46:24.50  Dispensing from Rack 4x7 vessel 10 to Rack RV48 vessel 11 
21:46:26.42  Pick up 4000 microL and 0 steps 
21:46:30.59  A1200R 
21:46:44.93  Pick up 110 microL and 0 steps 
21:46:45.64  A33R 
21:46:46.03  Dispense 99 microL and 0 steps 
21:46:46.03  A30R 
21:46:48.88  --Cleaned Probe with 4000µl of DMF (1) 
21:46:49.60  Pick up 110 microL and 0 steps 
21:46:49.98  A33R 
21:46:50.37  Dispense 99 microL and 0 steps 
21:46:50.37  A30R 
21:46:55.86  Pick up 924 microL and 0 steps 
21:46:58.66  A277R 
21:47:02.28  Dispense 823 microL and 0 steps 
21:47:02.28  A247R 
21:47:08.38  --Aspirated 698µl from 4x7[10](Leu) 
21:47:10.41  Dispense 0 microL and 0 steps 
21:47:10.41  A0R 
21:47:15.80  --Dispensed 823µl to RV48[11] 
21:47:19.09  30 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=155 
21:47:19.09  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
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21:47:19.09  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
21:47:21.01  Pick up 2250 microL and 0 steps 
21:47:23.43  A675R 
21:47:36.01  Pick up 110 microL and 0 steps 
21:47:36.72  A33R 
21:47:37.11  Dispense 99 microL and 0 steps 
21:47:37.11  A30R 
21:47:40.02  --Cleaned Probe with 2250µl of DMF (1) 
21:47:40.68  Pick up 110 microL and 0 steps 
21:47:41.06  A33R 
21:47:41.45  Dispense 99 microL and 0 steps 
21:47:41.45  A30R 
21:47:47.87  Pick up 924 microL and 0 steps 
21:47:50.67  A277R 
21:47:54.52  Dispense 823 microL and 0 steps 
21:47:54.52  A247R 
21:48:00.84  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
21:48:03.09  Dispense 124 microL and 0 steps 
21:48:03.09  A37R 
21:48:08.25  --Dispensed 700µl to RV48[11] 
21:48:08.69  Dispense 0 microL and 0 steps 
21:48:08.69  A0R 
21:48:12.97  --Dispensed 123µl to RV48[11] 
21:48:16.27  31 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=156 
21:48:16.27  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
21:48:16.32  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
21:48:18.19  Pick up 2250 microL and 0 steps 
21:48:20.61  A675R 
21:48:33.19  Pick up 110 microL and 0 steps 
21:48:33.96  A33R 
21:48:34.28  Dispense 99 microL and 0 steps 
21:48:34.28  A30R 
21:48:37.20  --Cleaned Probe with 2250µl of DMF (1) 
21:48:37.86  Pick up 110 microL and 0 steps 
21:48:38.29  A33R 
21:48:38.62  Dispense 99 microL and 0 steps 
21:48:38.62  A30R 
21:48:44.83  Pick up 924 microL and 0 steps 
21:48:47.63  A277R 
21:48:51.42  Dispense 823 microL and 0 steps 
21:48:51.42  A247R 
21:48:57.74  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
21:48:59.99  Dispense 124 microL and 0 steps 
21:48:59.99  A37R 
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21:49:05.21  --Dispensed 700µl to RV48[11] 
21:49:05.65  Dispense 0 microL and 0 steps 
21:49:05.65  A0R 
21:49:09.99  --Dispensed 123µl to RV48[11] 
21:49:13.28  32 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=157 
21:49:15.04  Mixer 0 on at 450 rpm 
22:34:18.47  Mixer 0 off 
22:34:18.80  33 Empty RV48 for 1.500 minute(s) SynthPos=158 
22:35:46.46  34 Goto ChemFile washcp48.cht, line 1 SynthPos=159 
22:35:47.78  1 REM Wash after Coupling SynthPos=160 
22:35:48.17  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=161 
22:36:19.20  Washing with DMF (A) 3.00ml per vessel to RV48 
22:36:29.14  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=162 
22:36:30.90  Mixer 0 on at 450 rpm 
22:37:32.30  Mixer 0 off 
22:37:32.63  4 Empty RV48 for 1.500 minute(s) SynthPos=163 
22:39:00.46  5 Repeat from step 2, 3 times SynthPos=164 
22:39:01.78  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=165 
22:39:01.94  Washing with DMF (A) 3.00ml per vessel to RV48 
22:39:11.88  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=166 
22:39:13.64  Mixer 0 on at 450 rpm 
22:40:16.48  Mixer 0 off 
22:40:16.81  4 Empty RV48 for 1.500 minute(s) SynthPos=167 
22:41:44.47  5 Repeat from step 2, 3 times SynthPos=168 
22:41:45.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=169 
22:41:45.95  Washing with DMF (A) 3.00ml per vessel to RV48 
22:41:55.89  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=170 
22:41:57.65  Mixer 0 on at 450 rpm 
22:42:59.17  Mixer 0 off 
22:42:59.50  4 Empty RV48 for 1.500 minute(s) SynthPos=171 
22:44:27.49  5 Repeat from step 2, 3 times SynthPos=172 
22:44:28.80  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=173 
22:44:28.97  Washing with DMF (A) 3.00ml per vessel to RV48 
22:44:38.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=174 
22:44:40.67  Mixer 0 on at 450 rpm 
22:45:43.01  Mixer 0 off 
22:45:43.34  4 Empty RV48 for 1.500 minute(s) SynthPos=175 
22:47:11.44  5 Repeat from step 2, 3 times SynthPos=176 
22:47:12.76  6 Return SynthPos=177 
22:47:13.14  35 REM ** This is the data for cycle 4. ** SynthPos=178 
22:47:13.47  36 <Set Active> SynthPos=179 
22:47:14.95  37 Goto ChemFile depro48.cht, line 1 SynthPos=180 
22:47:16.27  1 REM FMOC DEPROTECTION SynthPos=181 
22:47:16.60  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=182 
22:47:16.60  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
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… 
22:47:16.66  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
22:47:18.52  Pick up 2250 microL and 0 steps 
22:47:21.00  A675R 
22:47:33.52  Pick up 110 microL and 0 steps 
22:47:34.29  A33R 
22:47:34.67  Dispense 99 microL and 0 steps 
22:47:34.67  A30R 
22:47:37.53  --Cleaned Probe with 2250µl of DMF (1) 
22:47:38.24  Pick up 110 microL and 0 steps 
22:47:38.63  A33R 
22:47:39.01  Dispense 99 microL and 0 steps 
22:47:39.01  A30R 
22:47:45.00  Pick up 2225 microL and 0 steps 
22:47:51.70  A668R 
22:47:55.49  Dispense 2126 microL and 0 steps 
22:47:55.49  A638R 
22:48:01.81  --Aspirated 2001µl from Pip-350mL[1](PIP) 
22:48:04.06  Dispense 126 microL and 0 steps 
22:48:04.06  A38R 
22:48:11.20  --Dispensed 2000µl to RV48[11] 
22:48:11.58  Dispense 1 microL and 0 steps 
22:48:11.58  A0R 
22:48:15.92  --Dispensed 126µl to RV48[11] 
22:48:19.22  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=183 
22:48:20.97  Mixer 0 on at 450 rpm 
22:51:22.28  Mixer 0 off 
22:51:22.67  4 Empty RV48 for 1.500 minute(s) SynthPos=184 
22:52:50.44  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=185 
22:52:50.44  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
22:52:50.44  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
22:52:51.15  Pick up 110 microL and 0 steps 
22:52:51.87  A33R 
22:52:52.25  Dispense 99 microL and 0 steps 
22:52:52.25  A30R 
22:52:58.24  Pick up 2225 microL and 0 steps 
22:53:04.94  A668R 
22:53:08.73  Dispense 2126 microL and 0 steps 
22:53:08.73  A638R 
22:53:14.88  --Aspirated 2001µl from Pip-350mL[1](PIP) 
22:53:17.08  Dispense 126 microL and 0 steps 
22:53:17.08  A38R 
22:53:24.22  --Dispensed 2000µl to RV48[11] 
22:53:24.66  Dispense 1 microL and 0 steps 
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22:53:24.66  A0R 
22:53:28.94  --Dispensed 126µl to RV48[11] 
22:53:32.24  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=186 
22:53:34.05  Mixer 0 on at 450 rpm 
23:01:36.57  Mixer 0 off 
23:01:36.90  7 Empty RV48 for 1.500 minute(s) SynthPos=187 
23:03:05.44  8 Return SynthPos=188 
23:03:05.77  38 Goto ChemFile washdp48.cht, line 1 SynthPos=189 
23:03:07.14  1 REM Wash after Deprotection SynthPos=190 
23:03:07.47  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=191 
23:03:38.50  Washing with DMF (B) 3.00ml per vessel to RV48 
23:03:48.45  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=192 
23:03:50.20  Mixer 0 on at 450 rpm 
23:04:52.43  Mixer 0 off 
23:04:52.76  4 Empty RV48 for 1.500 minute(s) SynthPos=193 
23:06:20.48  5 Repeat from step 2, 3 times SynthPos=194 
23:06:21.80  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=195 
23:06:21.96  Washing with DMF (B) 3.00ml per vessel to RV48 
23:06:31.85  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=196 
23:06:33.66  Mixer 0 on at 450 rpm 
23:07:35.29  Mixer 0 off 
23:07:35.67  4 Empty RV48 for 1.500 minute(s) SynthPos=197 
23:09:03.44  5 Repeat from step 2, 3 times SynthPos=198 
23:09:04.76  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=199 
23:09:04.93  Washing with DMF (B) 3.00ml per vessel to RV48 
23:09:14.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=200 
23:09:16.63  Mixer 0 on at 450 rpm 
23:10:18.25  Mixer 0 off 
23:10:18.58  4 Empty RV48 for 1.500 minute(s) SynthPos=201 
23:11:46.46  5 Repeat from step 2, 3 times SynthPos=202 
23:11:47.78  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=203 
23:11:47.95  Washing with DMF (B) 3.00ml per vessel to RV48 
23:11:57.83  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=204 
23:11:59.65  Mixer 0 on at 450 rpm 
23:13:01.44  Mixer 0 off 
23:13:01.77  4 Empty RV48 for 1.500 minute(s) SynthPos=205 
23:14:29.48  5 Repeat from step 2, 3 times SynthPos=206 
23:14:30.80  6 Return SynthPos=207 
23:14:31.18  39 REM HBTU48 SynthPos=208 
23:14:31.51  40 Dispense Sequence SNI144.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=209 
23:14:31.51  Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11 
23:14:33.44  Pick up 4000 microL and 0 steps 
23:14:37.61  A1200R 
23:14:51.95  Pick up 110 microL and 0 steps 
23:14:52.72  A33R 
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23:14:53.04  Dispense 99 microL and 0 steps 
23:14:53.04  A30R 
23:14:55.96  --Cleaned Probe with 4000µl of DMF (1) 
23:14:56.67  Pick up 110 microL and 0 steps 
23:14:57.05  A33R 
23:14:57.38  Dispense 99 microL and 0 steps 
23:14:57.38  A30R 
23:15:02.99  Pick up 924 microL and 0 steps 
23:15:05.79  A277R 
23:15:09.47  Dispense 823 microL and 0 steps 
23:15:09.47  A247R 
23:15:15.56  --Aspirated 698µl from 4x7[13](Phe) 
23:15:17.49  Dispense 0 microL and 0 steps 
23:15:17.49  A0R 
23:15:22.81  --Dispensed 823µl to RV48[11] 
23:15:26.11  41 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=210 
23:15:26.11  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
23:15:26.11  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
23:15:28.03  Pick up 2250 microL and 0 steps 
23:15:30.45  A675R 
23:15:42.97  Pick up 110 microL and 0 steps 
23:15:43.74  A33R 
23:15:44.13  Dispense 99 microL and 0 steps 
23:15:44.13  A30R 
23:15:46.98  --Cleaned Probe with 2250µl of DMF (1) 
23:15:47.70  Pick up 110 microL and 0 steps 
23:15:48.08  A33R 
23:15:48.46  Dispense 99 microL and 0 steps 
23:15:48.46  A30R 
23:15:54.89  Pick up 924 microL and 0 steps 
23:15:57.64  A277R 
23:16:01.48  Dispense 823 microL and 0 steps 
23:16:01.48  A247R 
23:16:07.80  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
23:16:10.05  Dispense 124 microL and 0 steps 
23:16:10.05  A37R 
23:16:15.27  --Dispensed 700µl to RV48[11] 
23:16:15.65  Dispense 0 microL and 0 steps 
23:16:15.65  A0R 
23:16:19.99  --Dispensed 123µl to RV48[11] 
23:16:23.23  42 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=211 
23:16:23.23  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
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23:16:23.29  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
23:16:25.15  Pick up 2250 microL and 0 steps 
23:16:27.63  A675R 
23:16:40.15  Pick up 110 microL and 0 steps 
23:16:40.92  A33R 
23:16:41.25  Dispense 99 microL and 0 steps 
23:16:41.25  A30R 
23:16:44.16  --Cleaned Probe with 2250µl of DMF (1) 
23:16:44.82  Pick up 110 microL and 0 steps 
23:16:45.26  A33R 
23:16:45.59  Dispense 99 microL and 0 steps 
23:16:45.59  A30R 
23:16:51.79  Pick up 924 microL and 0 steps 
23:16:54.59  A277R 
23:16:58.38  Dispense 823 microL and 0 steps 
23:16:58.38  A247R 
23:17:04.76  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
23:17:06.95  Dispense 124 microL and 0 steps 
23:17:06.95  A37R 
23:17:12.17  --Dispensed 700µl to RV48[11] 
23:17:12.56  Dispense 0 microL and 0 steps 
23:17:12.56  A0R 
23:17:16.89  --Dispensed 123µl to RV48[11] 
23:17:20.19  43 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=212 
23:17:21.95  Mixer 0 on at 450 rpm 
00:02:23.30  Mixer 0 off 
00:02:23.63  44 Empty RV48 for 1.500 minute(s) SynthPos=213 
00:03:51.45  45 Goto ChemFile washcp48.cht, line 1 SynthPos=214 
00:03:52.77  1 REM Wash after Coupling SynthPos=215 
00:03:53.15  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=216 
00:04:24.19  Washing with DMF (A) 3.00ml per vessel to RV48 
00:04:34.13  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=217 
00:04:35.89  Mixer 0 on at 450 rpm 
00:05:37.40  Mixer 0 off 
00:05:37.73  4 Empty RV48 for 1.500 minute(s) SynthPos=218 
00:07:05.45  5 Repeat from step 2, 3 times SynthPos=219 
00:07:06.77  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=220 
00:07:06.93  Washing with DMF (A) 3.00ml per vessel to RV48 
00:07:16.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=221 
00:07:18.63  Mixer 0 on at 450 rpm 
00:08:19.98  Mixer 0 off 
00:08:20.31  4 Empty RV48 for 1.500 minute(s) SynthPos=222 
00:09:48.47  5 Repeat from step 2, 3 times SynthPos=223 
00:09:49.78  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=224 
00:09:49.95  Washing with DMF (A) 3.00ml per vessel to RV48 
00:09:59.89  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=225 
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00:10:01.65  Mixer 0 on at 450 rpm 
00:11:03.55  Mixer 0 off 
00:11:03.88  4 Empty RV48 for 1.500 minute(s) SynthPos=226 
00:12:31.49  5 Repeat from step 2, 3 times SynthPos=227 
00:12:32.80  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=228 
00:12:32.97  Washing with DMF (A) 3.00ml per vessel to RV48 
00:12:42.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=229 
00:12:44.67  Mixer 0 on at 450 rpm 
00:13:46.35  Mixer 0 off 
00:13:46.68  4 Empty RV48 for 1.500 minute(s) SynthPos=230 
00:15:14.45  5 Repeat from step 2, 3 times SynthPos=231 
00:15:15.77  6 Return SynthPos=232 
00:15:16.15  46 REM ** This is the data for cycle 5. ** SynthPos=233 
00:15:16.48  47 <Set Active> SynthPos=234 
00:15:17.96  48 Goto ChemFile depro48.cht, line 1 SynthPos=235 
00:15:19.28  1 REM FMOC DEPROTECTION SynthPos=236 
00:15:19.67  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=237 
00:15:19.67  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
00:15:19.67  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
00:15:21.59  Pick up 2250 microL and 0 steps 
00:15:24.01  A675R 
00:15:36.53  Pick up 110 microL and 0 steps 
00:15:37.30  A33R 
00:15:37.63  Dispense 99 microL and 0 steps 
00:15:37.63  A30R 
00:15:40.54  --Cleaned Probe with 2250µl of DMF (1) 
00:15:41.25  Pick up 110 microL and 0 steps 
00:15:41.64  A33R 
00:15:42.02  Dispense 99 microL and 0 steps 
00:15:42.02  A30R 
00:15:48.01  Pick up 2225 microL and 0 steps 
00:15:54.71  A668R 
00:15:58.50  Dispense 2126 microL and 0 steps 
00:15:58.50  A638R 
00:16:04.87  --Aspirated 2001µl from Pip-350mL[1](PIP) 
00:16:07.07  Dispense 126 microL and 0 steps 
00:16:07.07  A38R 
00:16:14.21  --Dispensed 2000µl to RV48[11] 
00:16:14.65  Dispense 1 microL and 0 steps 
00:16:14.65  A0R 
00:16:18.93  --Dispensed 126µl to RV48[11] 
00:16:22.23  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=238 
00:16:24.04  Mixer 0 on at 450 rpm 
00:19:26.28  Mixer 0 off 
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00:19:26.61  4 Empty RV48 for 1.500 minute(s) SynthPos=239 
00:20:54.44  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=240 
00:20:54.44  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
00:20:54.44  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
00:20:55.10  Pick up 110 microL and 0 steps 
00:20:55.87  A33R 
00:20:56.25  Dispense 99 microL and 0 steps 
00:20:56.25  A30R 
00:21:02.24  Pick up 2225 microL and 0 steps 
00:21:08.94  A668R 
00:21:12.73  Dispense 2126 microL and 0 steps 
00:21:12.73  A638R 
00:21:18.88  --Aspirated 2001µl from Pip-350mL[1](PIP) 
00:21:21.08  Dispense 126 microL and 0 steps 
00:21:21.08  A38R 
00:21:28.22  --Dispensed 2000µl to RV48[11] 
00:21:28.66  Dispense 1 microL and 0 steps 
00:21:28.66  A0R 
00:21:32.94  --Dispensed 126µl to RV48[11] 
00:21:36.24  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=241 
00:21:38.05  Mixer 0 on at 450 rpm 
00:29:41.01  Mixer 0 off 
00:29:41.34  7 Empty RV48 for 1.500 minute(s) SynthPos=242 
00:31:09.44  8 Return SynthPos=243 
00:31:09.77  49 Goto ChemFile washdp48.cht, line 1 SynthPos=244 
00:31:11.09  1 REM Wash after Deprotection SynthPos=245 
00:31:11.47  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=246 
00:31:42.50  Washing with DMF (B) 3.00ml per vessel to RV48 
00:31:52.45  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=247 
00:31:54.20  Mixer 0 on at 450 rpm 
00:32:56.65  Mixer 0 off 
00:32:57.04  4 Empty RV48 for 1.500 minute(s) SynthPos=248 
00:34:25.47  5 Repeat from step 2, 3 times SynthPos=249 
00:34:26.79  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=250 
00:34:26.95  Washing with DMF (B) 3.00ml per vessel to RV48 
00:34:36.84  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=251 
00:34:38.65  Mixer 0 on at 450 rpm 
00:35:40.28  Mixer 0 off 
00:35:40.61  4 Empty RV48 for 1.500 minute(s) SynthPos=252 
00:37:08.49  5 Repeat from step 2, 3 times SynthPos=253 
00:37:09.81  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=254 
00:37:09.97  Washing with DMF (B) 3.00ml per vessel to RV48 
00:37:19.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=255 
00:37:21.67  Mixer 0 on at 450 rpm 
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00:38:23.24  Mixer 0 off 
00:38:23.57  4 Empty RV48 for 1.500 minute(s) SynthPos=256 
00:39:51.45  5 Repeat from step 2, 3 times SynthPos=257 
00:39:52.77  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=258 
00:39:52.93  Washing with DMF (B) 3.00ml per vessel to RV48 
00:40:02.88  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=259 
00:40:04.63  Mixer 0 on at 450 rpm 
00:41:06.15  Mixer 0 off 
00:41:06.48  4 Empty RV48 for 1.500 minute(s) SynthPos=260 
00:42:34.47  5 Repeat from step 2, 3 times SynthPos=261 
00:42:35.79  6 Return SynthPos=262 
00:42:36.17  50 REM HBTU48 SynthPos=263 
00:42:36.50  51 Dispense Sequence SNI145.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=264 
00:42:36.50  Dispensing from Rack 4x7 vessel 10 to Rack RV48 vessel 11 
00:42:38.42  Pick up 4000 microL and 0 steps 
00:42:42.60  A1200R 
00:42:56.93  Pick up 110 microL and 0 steps 
00:42:57.70  A33R 
00:42:58.03  Dispense 99 microL and 0 steps 
00:42:58.03  A30R 
00:43:00.94  --Cleaned Probe with 4000µl of DMF (1) 
00:43:01.60  Pick up 110 microL and 0 steps 
00:43:02.04  A33R 
00:43:02.37  Dispense 99 microL and 0 steps 
00:43:02.37  A30R 
00:43:07.86  Pick up 924 microL and 0 steps 
00:43:10.67  A277R 
00:43:14.29  Dispense 823 microL and 0 steps 
00:43:14.29  A247R 
00:43:20.44  --Aspirated 698µl from 4x7[10](Leu) 
00:43:22.47  Dispense 0 microL and 0 steps 
00:43:22.47  A0R 
00:43:27.86  --Dispensed 823µl to RV48[11] 
00:43:31.10  52 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=265 
00:43:31.10  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
00:43:31.10  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
00:43:33.02  Pick up 2250 microL and 0 steps 
00:43:35.44  A675R 
00:43:48.02  Pick up 110 microL and 0 steps 
00:43:48.78  A33R 
00:43:49.11  Dispense 99 microL and 0 steps 
00:43:49.11  A30R 
00:43:52.02  --Cleaned Probe with 2250µl of DMF (1) 
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00:43:52.68  Pick up 110 microL and 0 steps 
00:43:53.12  A33R 
00:43:53.45  Dispense 99 microL and 0 steps 
00:43:53.45  A30R 
00:43:59.88  Pick up 924 microL and 0 steps 
00:44:02.68  A277R 
00:44:06.47  Dispense 823 microL and 0 steps 
00:44:06.47  A247R 
00:44:12.79  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
00:44:15.04  Dispense 124 microL and 0 steps 
00:44:15.04  A37R 
00:44:20.26  --Dispensed 700µl to RV48[11] 
00:44:20.64  Dispense 0 microL and 0 steps 
00:44:20.64  A0R 
00:44:24.98  --Dispensed 123µl to RV48[11] 
00:44:28.28  53 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=266 
00:44:28.28  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
00:44:28.28  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
00:44:30.14  Pick up 2250 microL and 0 steps 
00:44:32.61  A675R 
00:44:45.14  Pick up 110 microL and 0 steps 
00:44:45.91  A33R 
00:44:46.24  Dispense 99 microL and 0 steps 
00:44:46.24  A30R 
00:44:49.15  --Cleaned Probe with 2250µl of DMF (1) 
00:44:49.81  Pick up 110 microL and 0 steps 
00:44:50.25  A33R 
00:44:50.58  Dispense 99 microL and 0 steps 
00:44:50.58  A30R 
00:44:56.78  Pick up 924 microL and 0 steps 
00:44:59.58  A277R 
00:45:03.43  Dispense 823 microL and 0 steps 
00:45:03.43  A247R 
00:45:09.74  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
00:45:12.00  Dispense 124 microL and 0 steps 
00:45:12.00  A37R 
00:45:17.16  --Dispensed 700µl to RV48[11] 
00:45:17.60  Dispense 0 microL and 0 steps 
00:45:17.60  A0R 
00:45:21.88  --Dispensed 123µl to RV48[11] 
00:45:25.18  54 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=267 
00:45:26.99  Mixer 0 on at 450 rpm 
01:30:28.28  Mixer 0 off 
01:30:28.61  55 Empty RV48 for 1.500 minute(s) SynthPos=268 
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01:31:56.44  56 Goto ChemFile washcp48.cht, line 1 SynthPos=269 
01:31:57.76  1 REM Wash after Coupling SynthPos=270 
01:31:58.14  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=271 
01:32:29.17  Washing with DMF (A) 3.00ml per vessel to RV48 
01:32:39.11  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=272 
01:32:40.87  Mixer 0 on at 450 rpm 
01:33:42.22  Mixer 0 off 
01:33:42.55  4 Empty RV48 for 1.500 minute(s) SynthPos=273 
01:35:10.49  5 Repeat from step 2, 3 times SynthPos=274 
01:35:11.81  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=275 
01:35:11.97  Washing with DMF (A) 3.00ml per vessel to RV48 
01:35:21.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=276 
01:35:23.67  Mixer 0 on at 450 rpm 
01:36:25.08  Mixer 0 off 
01:36:25.41  4 Empty RV48 for 1.500 minute(s) SynthPos=277 
01:37:53.45  5 Repeat from step 2, 3 times SynthPos=278 
01:37:54.77  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=279 
01:37:54.94  Washing with DMF (A) 3.00ml per vessel to RV48 
01:38:04.88  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=280 
01:38:06.63  Mixer 0 on at 450 rpm 
01:39:07.77  Mixer 0 off 
01:39:08.10  4 Empty RV48 for 1.500 minute(s) SynthPos=281 
01:40:36.47  5 Repeat from step 2, 3 times SynthPos=282 
01:40:37.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=283 
01:40:37.95  Washing with DMF (A) 3.00ml per vessel to RV48 
01:40:47.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=284 
01:40:49.65  Mixer 0 on at 450 rpm 
01:41:51.44  Mixer 0 off 
01:41:51.77  4 Empty RV48 for 1.500 minute(s) SynthPos=285 
01:43:19.44  5 Repeat from step 2, 3 times SynthPos=286 
01:43:20.75  6 Return SynthPos=287 
01:43:21.14  57 REM ** This is the data for cycle 6. ** SynthPos=288 
01:43:21.47  58 <Set Active> SynthPos=289 
01:43:22.95  59 Goto ChemFile depro48.cht, line 1 SynthPos=290 
01:43:24.27  1 REM FMOC DEPROTECTION SynthPos=291 
01:43:24.65  2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=292 
01:43:24.65  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
01:43:24.65  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
01:43:26.52  Pick up 2250 microL and 0 steps 
01:43:28.99  A675R 
01:43:41.52  Pick up 110 microL and 0 steps 
01:43:42.28  A33R 
01:43:42.67  Dispense 99 microL and 0 steps 
01:43:42.67  A30R 
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01:43:45.53  --Cleaned Probe with 2250µl of DMF (1) 
01:43:46.24  Pick up 110 microL and 0 steps 
01:43:46.68  A33R 
01:43:47.01  Dispense 99 microL and 0 steps 
01:43:47.01  A30R 
01:43:52.99  Pick up 2225 microL and 0 steps 
01:43:59.70  A668R 
01:44:03.49  Dispense 2126 microL and 0 steps 
01:44:03.49  A638R 
01:44:09.86  --Aspirated 2001µl from Pip-350mL[1](PIP) 
01:44:12.05  Dispense 126 microL and 0 steps 
01:44:12.05  A38R 
01:44:19.19  --Dispensed 2000µl to RV48[11] 
01:44:19.58  Dispense 1 microL and 0 steps 
01:44:19.58  A0R 
01:44:23.92  --Dispensed 126µl to RV48[11] 
01:44:27.21  3 Mix "RV48"  for 3.00 minutes  at 450 rpm(s) and wait. SynthPos=293 
01:44:28.97  Mixer 0 on at 450 rpm 
01:47:30.28  Mixer 0 off 
01:47:30.66  4 Empty RV48 for 1.500 minute(s) SynthPos=294 
01:48:58.44  5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1) 
SynthPos=295 
01:48:58.44  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
01:48:58.44  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
01:48:59.09  Pick up 110 microL and 0 steps 
01:48:59.86  A33R 
01:49:00.25  Dispense 99 microL and 0 steps 
01:49:00.25  A30R 
01:49:06.23  Pick up 2225 microL and 0 steps 
01:49:12.94  A668R 
01:49:16.73  Dispense 2126 microL and 0 steps 
01:49:16.73  A638R 
01:49:22.88  --Aspirated 2001µl from Pip-350mL[1](PIP) 
01:49:25.07  Dispense 126 microL and 0 steps 
01:49:25.07  A38R 
01:49:32.21  --Dispensed 2000µl to RV48[11] 
01:49:32.65  Dispense 1 microL and 0 steps 
01:49:32.65  A0R 
01:49:36.94  --Dispensed 126µl to RV48[11] 
01:49:40.23  6 Mix "RV48"  for 8.00 minutes  at 450 rpm(s) and wait. SynthPos=296 
01:49:42.05  Mixer 0 on at 450 rpm 
01:57:44.62  Mixer 0 off 
01:57:45.01  7 Empty RV48 for 1.500 minute(s) SynthPos=297 
01:59:13.44  8 Return SynthPos=298 
01:59:13.77  60 Goto ChemFile washdp48.cht, line 1 SynthPos=299 
87 
 
01:59:15.14  1 REM Wash after Deprotection SynthPos=300 
01:59:15.47  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=301 
01:59:46.50  Washing with DMF (B) 3.00ml per vessel to RV48 
01:59:56.44  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=302 
01:59:58.20  Mixer 0 on at 450 rpm 
02:01:00.32  Mixer 0 off 
02:01:00.65  4 Empty RV48 for 1.500 minute(s) SynthPos=303 
02:02:28.48  5 Repeat from step 2, 3 times SynthPos=304 
02:02:29.79  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=305 
02:02:29.96  Washing with DMF (B) 3.00ml per vessel to RV48 
02:02:39.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=306 
02:02:41.66  Mixer 0 on at 450 rpm 
02:03:43.18  Mixer 0 off 
02:03:43.50  4 Empty RV48 for 1.500 minute(s) SynthPos=307 
02:05:11.44  5 Repeat from step 2, 3 times SynthPos=308 
02:05:12.76  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=309 
02:05:12.92  Washing with DMF (B) 3.00ml per vessel to RV48 
02:05:22.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=310 
02:05:24.62  Mixer 0 on at 450 rpm 
02:06:26.14  Mixer 0 off 
02:06:26.52  4 Empty RV48 for 1.500 minute(s) SynthPos=311 
02:07:54.46  5 Repeat from step 2, 3 times SynthPos=312 
02:07:55.78  2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=313 
02:07:55.94  Washing with DMF (B) 3.00ml per vessel to RV48 
02:08:05.83  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=314 
02:08:07.64  Mixer 0 on at 450 rpm 
02:09:09.82  Mixer 0 off 
02:09:10.15  4 Empty RV48 for 1.500 minute(s) SynthPos=315 
02:10:38.47  5 Repeat from step 2, 3 times SynthPos=316 
02:10:39.79  6 Return SynthPos=317 
02:10:40.17  61 REM HBTU48 SynthPos=318 
02:10:40.50  62 Dispense Sequence SNI146.dsp with 0.699ml to RV48 rack using DMF 
(1) SynthPos=319 
02:10:40.50  Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11 
02:10:42.42  Pick up 4000 microL and 0 steps 
02:10:46.60  A1200R 
02:11:00.93  Pick up 110 microL and 0 steps 
02:11:01.70  A33R 
02:11:02.03  Dispense 99 microL and 0 steps 
02:11:02.03  A30R 
02:11:04.94  --Cleaned Probe with 4000µl of DMF (1) 
02:11:05.66  Pick up 110 microL and 0 steps 
02:11:06.04  A33R 
02:11:06.37  Dispense 99 microL and 0 steps 
02:11:06.37  A30R 
02:11:12.03  Pick up 924 microL and 0 steps 
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02:11:14.77  A277R 
02:11:18.45  Dispense 823 microL and 0 steps 
02:11:18.45  A247R 
02:11:24.55  --Aspirated 698µl from 4x7[13](Phe) 
02:11:26.47  Dispense 0 microL and 0 steps 
02:11:26.47  A0R 
02:11:31.80  --Dispensed 823µl to RV48[11] 
02:11:35.10  63 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using 
DMF (1) SynthPos=320 
02:11:35.10  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 
02:11:35.10  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
02:11:37.02  Pick up 2250 microL and 0 steps 
02:11:39.43  A675R 
02:11:51.96  Pick up 110 microL and 0 steps 
02:11:52.73  A33R 
02:11:53.11  Dispense 99 microL and 0 steps 
02:11:53.11  A30R 
02:11:55.97  --Cleaned Probe with 2250µl of DMF (1) 
02:11:56.68  Pick up 110 microL and 0 steps 
02:11:57.07  A33R 
02:11:57.45  Dispense 99 microL and 0 steps 
02:11:57.45  A30R 
02:12:03.88  Pick up 924 microL and 0 steps 
02:12:06.68  A277R 
02:12:10.52  Dispense 823 microL and 0 steps 
02:12:10.52  A247R 
02:12:16.84  --Aspirated 698µl from HBTU-350mL[1](HCTU) 
02:12:19.04  Dispense 124 microL and 0 steps 
02:12:19.04  A37R 
02:12:24.25  --Dispensed 700µl to RV48[11] 
02:12:24.69  Dispense 0 microL and 0 steps 
02:12:24.69  A0R 
02:12:28.98  --Dispensed 123µl to RV48[11] 
02:12:32.27  64 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using 
DMF (1) SynthPos=321 
02:12:32.27  RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47 
… 7 
02:12:32.27  RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1 
02:12:34.20  Pick up 2250 microL and 0 steps 
02:12:36.61  A675R 
02:12:49.19  Pick up 110 microL and 0 steps 
02:12:49.90  A33R 
02:12:50.29  Dispense 99 microL and 0 steps 
02:12:50.29  A30R 
02:12:53.14  --Cleaned Probe with 2250µl of DMF (1) 
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02:12:53.86  Pick up 110 microL and 0 steps 
02:12:54.24  A33R 
02:12:54.63  Dispense 99 microL and 0 steps 
02:12:54.63  A30R 
02:13:00.83  Pick up 924 microL and 0 steps 
02:13:03.64  A277R 
02:13:07.43  Dispense 823 microL and 0 steps 
02:13:07.43  A247R 
02:13:13.80  --Aspirated 698µl from DIEA-350mL[1](DIPEA) 
02:13:15.99  Dispense 124 microL and 0 steps 
02:13:15.99  A37R 
02:13:21.21  --Dispensed 700µl to RV48[11] 
02:13:21.65  Dispense 0 microL and 0 steps 
02:13:21.65  A0R 
02:13:25.93  --Dispensed 123µl to RV48[11] 
02:13:29.23  65 Mix "RV48"  for 45.00 minutes  at 450 rpm(s) and wait. SynthPos=322 
02:13:30.99  Mixer 0 on at 450 rpm 
02:58:32.44  Mixer 0 off 
02:58:32.77  66 Empty RV48 for 1.500 minute(s) SynthPos=323 
03:00:00.49  67 Goto ChemFile washcp48.cht, line 1 SynthPos=324 
03:00:01.81  1 REM Wash after Coupling SynthPos=325 
03:00:02.19  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=326 
03:00:33.22  Washing with DMF (A) 3.00ml per vessel to RV48 
03:00:43.17  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=327 
03:00:44.92  Mixer 0 on at 450 rpm 
03:01:46.71  Mixer 0 off 
03:01:47.04  4 Empty RV48 for 1.500 minute(s) SynthPos=328 
03:03:15.47  5 Repeat from step 2, 3 times SynthPos=329 
03:03:16.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=330 
03:03:16.96  Washing with DMF (A) 3.00ml per vessel to RV48 
03:03:26.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=331 
03:03:28.66  Mixer 0 on at 450 rpm 
03:04:29.90  Mixer 0 off 
03:04:30.28  4 Empty RV48 for 1.500 minute(s) SynthPos=332 
03:05:58.44  5 Repeat from step 2, 3 times SynthPos=333 
03:05:59.76  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=334 
03:05:59.92  Washing with DMF (A) 3.00ml per vessel to RV48 
03:06:09.86  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=335 
03:06:11.62  Mixer 0 on at 450 rpm 
03:07:13.52  Mixer 0 off 
03:07:13.91  4 Empty RV48 for 1.500 minute(s) SynthPos=336 
03:08:42.45  5 Repeat from step 2, 3 times SynthPos=337 
03:08:43.76  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=338 
03:08:43.93  Washing with DMF (A) 3.00ml per vessel to RV48 
03:08:53.87  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=339 
03:08:55.63  Mixer 0 on at 450 rpm 
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03:09:57.64  Mixer 0 off 
03:09:58.02  4 Empty RV48 for 1.500 minute(s) SynthPos=340 
03:11:26.45  5 Repeat from step 2, 3 times SynthPos=341 
03:11:27.77  6 Return SynthPos=342 
03:11:28.16  68 Goto ChemFile washfn48.cht, line 1 SynthPos=343 
03:11:29.47  1 Goto ChemFile C:\AAPPTEC\WASHCP48.CHM, line 1 SynthPos=344 
03:11:30.79  1 REM Wash after Coupling SynthPos=345 
03:11:31.18  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=346 
03:11:31.34  Washing with DMF (A) 3.00ml per vessel to RV48 
03:11:41.23  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=347 
03:11:43.04  Mixer 0 on at 450 rpm 
03:12:45.93  Mixer 0 off 
03:12:46.26  4 Empty RV48 for 1.500 minute(s) SynthPos=348 
03:14:14.47  5 Repeat from step 2, 3 times SynthPos=349 
03:14:15.79  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=350 
03:14:15.95  Washing with DMF (A) 3.00ml per vessel to RV48 
03:14:25.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=351 
03:14:27.65  Mixer 0 on at 450 rpm 
03:15:29.83  Mixer 0 off 
03:15:30.16  4 Empty RV48 for 1.500 minute(s) SynthPos=352 
03:16:58.48  5 Repeat from step 2, 3 times SynthPos=353 
03:16:59.80  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=354 
03:16:59.96  Washing with DMF (A) 3.00ml per vessel to RV48 
03:17:09.90  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=355 
03:17:11.66  Mixer 0 on at 450 rpm 
03:18:13.62  Mixer 0 off 
03:18:13.95  4 Empty RV48 for 1.500 minute(s) SynthPos=356 
03:19:42.49  5 Repeat from step 2, 3 times SynthPos=357 
03:19:43.80  2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=358 
03:19:43.97  Washing with DMF (A) 3.00ml per vessel to RV48 
03:19:53.91  3 Mix "RV48"  for 1.00 minutes  at 450 rpm(s) and wait. SynthPos=359 
03:19:55.67  Mixer 0 on at 450 rpm 
03:20:57.18  Mixer 0 off 
03:20:57.57  4 Empty RV48 for 1.500 minute(s) SynthPos=360 
03:22:25.45  5 Repeat from step 2, 3 times SynthPos=361 
03:22:26.77  6 Return SynthPos=362 
03:22:27.15  2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=363 
03:22:29.07  Pick up 9000 microL and 0 steps 
03:22:38.30  A2700R 
03:22:49.18  Pick up 9000 microL and 0 steps 
03:22:58.35  A2700R 
03:23:19.11  Pick up 40 microL and 0 steps 
03:23:19.61  A12R 
03:23:20.81  Dispense 29 microL and 0 steps 
03:23:20.81  A9R 
03:23:23.73  --Cleaned Probe with 18000µl of MEOH (2) 
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03:23:24.06  Pick up 3000 microL and 0 steps 
03:23:27.19  A900R 
03:23:27.84  --Aspirated 2999µl of System Fluid MEOH (2) 
03:23:31.31  Dispense 0 microL and 0 steps 
03:23:31.31  A0R 
03:23:40.37  --Dispensed 2999µl to RV48[11] 
03:23:43.22  3 Mix "RV48"  for 2.00 minutes  at 475 rpm(s) and wait. SynthPos=364 
03:23:45.26  Mixer 0 on at 475 rpm 
03:25:47.25  Mixer 0 off 
03:25:47.58  4 Empty RV48 for 3.000 minute(s) SynthPos=365 
03:28:45.48  5 Repeat from step 2, 2 times SynthPos=366 
03:28:46.80  2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=367 
03:28:47.18  Pick up 3000 microL and 0 steps 
03:28:50.37  A900R 
03:28:50.97  --Aspirated 2999µl of System Fluid MEOH (2) 
03:28:54.49  Dispense 0 microL and 0 steps 
03:28:54.49  A0R 
03:29:03.49  --Dispensed 2999µl to RV48[11] 
03:29:06.41  3 Mix "RV48"  for 2.00 minutes  at 475 rpm(s) and wait. SynthPos=368 
03:29:08.44  Mixer 0 on at 475 rpm 
03:31:11.69  Mixer 0 off 
03:31:12.02  4 Empty RV48 for 3.000 minute(s) SynthPos=369 
03:34:10.47  5 Repeat from step 2, 2 times SynthPos=370 
03:34:11.79  2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=371 
03:34:12.18  Pick up 3000 microL and 0 steps 
03:34:15.36  A900R 
03:34:15.97  --Aspirated 2999µl of System Fluid MEOH (2) 
03:34:19.48  Dispense 0 microL and 0 steps 
03:34:19.48  A0R 
03:34:28.54  --Dispensed 2999µl to RV48[11] 
03:34:31.40  3 Mix "RV48"  for 2.00 minutes  at 475 rpm(s) and wait. SynthPos=372 
03:34:33.43  Mixer 0 on at 475 rpm 
03:36:35.37  Mixer 0 off 
03:36:35.75  4 Empty RV48 for 3.000 minute(s) SynthPos=373 
03:39:33.44  5 Repeat from step 2, 2 times SynthPos=374 
03:39:34.75  6 Empty RV48 for 5.000 minute(s) SynthPos=375 
03:44:32.45  7 Return SynthPos=376 
03:44:39.81  Ending ChemFile - C:\AAPPTEC\SNI144.CHM  
  
92 
 
AUTHOR’S BIOGRAPHY 
 Sadie Novak was born in Kunming, China on February 22, 1997. She was 
adopted and raised in Akron, Ohio and Chautauqua, New York before moving to the 
beautiful state of Maine in 2014. In 2015, she graduated from Hampden Academy and 
began her undergraduate career at the University of Maine. Through her studies in 
organic chemistry, she discovered her love for the field and chose to pursue a degree in 
Chemistry. She has received a Center for Undergraduate Research grant and an Honors 
College Thesis Fellowship.  
While at the University of Maine, Sadie maintained an active role in the campus 
community through her involvement with the University of Maine College Democrats 
and Sophomore Eagles, as well as by serving as an officer for the Student Heritage 
Alliance Council. She also contributed to her community through the time she spent 
volunteering and interning for political campaigns.  
 Upon graduation, Sadie will return to New York to attend Syracuse 
University and earn her doctorate in biological organic chemistry.   
 
 
 
